

# A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model

Jakob Kreye<sup>1,2,3,4,†,\*</sup>, S Momsen Reincke<sup>1,2,3,5,†</sup>, Hans-Christian Kornau<sup>1,6</sup>, Elisa Sánchez-Sendin<sup>1,2,3</sup>, Victor Max Corman<sup>7</sup>, Hejun Liu<sup>8</sup>, Meng Yuan<sup>8</sup>, Nicholas C. Wu<sup>8</sup>, Xueyong Zhu<sup>8</sup>, Chang-Chun D. Lee<sup>8</sup>, Jakob Trimpert<sup>9</sup>, Markus Höltje<sup>10</sup>, Kristina Dietert<sup>11,12</sup>, Laura Stöffler<sup>1,3</sup>, Niels von Wardenburg<sup>1,3</sup>, Scott van Hoof<sup>1,2,3</sup>, Marie A Homeyer<sup>1,3,5</sup>, Julius Hoffmann<sup>1,3</sup>, Azza Abdelgawad<sup>9</sup>, Achim D Gruber<sup>11</sup>, Luca D Bertzbach<sup>9</sup>, Daria Vladimirova<sup>9</sup>, Lucie Y Li<sup>2,10</sup>, Paula Charlotte Barthel<sup>10</sup>, Karl Skriner<sup>13</sup>, Andreas C Hocke<sup>14</sup>, Stefan Hippenstiel<sup>14</sup>, Martin Witzenrath<sup>14</sup>, Norbert Suttorp<sup>14</sup>, Florian Kurth<sup>14,15</sup>, Christiana Franke<sup>3</sup>, Matthias Endres<sup>1,3,16,17,18</sup>, Dietmar Schmitz<sup>1,6</sup>, Lara Maria Jeworowski<sup>7</sup>, Anja Richter<sup>7</sup>, Marie Luisa Schmidt<sup>7</sup>, Tatjana Schwarz<sup>7</sup>, Marcel Alexander Müller<sup>7</sup>, Christian Drosten<sup>7</sup>, Daniel Wendisch<sup>14</sup>, Leif E Sander<sup>14</sup>, Nikolaus Osterrieder<sup>9</sup>, Ian A Wilson<sup>8,19</sup>, Harald Prüss<sup>1,2,3,\*</sup>

<sup>1</sup> German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.

<sup>2</sup> Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany.

<sup>3</sup> Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany.

<sup>4</sup> Department of Pediatric Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany.

<sup>5</sup> Berlin Institute of Health (BIH), 10178 Berlin, Germany.

<sup>6</sup> Neuroscience Research Center (NWFZ), Cluster NeuroCure, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany.

<sup>7</sup> Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, and German Centre for Infection Research (DZIF), Berlin, Germany.

<sup>8</sup> Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

<sup>9</sup> Institute of Virology, Freie Universität Berlin, Robert-von-Ostertag-Str. 7-13, 14163 Berlin, Germany.

<sup>10</sup> Institute of Integrative Neuroanatomy Berlin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

<sup>11</sup> Institute of Veterinary Pathology, Freie Universität Berlin, Robert-von-Ostertag-Str. 15, 14163 Berlin, Germany.

<sup>12</sup> Veterinary Centre for Resistance Research, Freie Universität Berlin, Robert-von-Ostertag-Str. 8, 14163 Berlin, Germany.

<sup>13</sup> Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany.

<sup>14</sup> Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany.

<sup>15</sup> Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine and I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

<sup>16</sup> Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany.

<sup>17</sup> Excellence Cluster NeuroCure Berlin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany.

<sup>18</sup> German Centre for Cardiovascular Research (DZHK), partner site Berlin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany.

<sup>19</sup> The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

† These authors contributed equally.

\* Correspondence to:

Jakob Kreye & Harald Prüss

German Center for Neurodegenerative Diseases (DZNE) Berlin

c/o Charité – Universitätsmedizin Berlin

CharitéCrossOver (CCO), Charitéplatz 1, 10117 Berlin, Germany

Email: [jakob.kreye@dzne.de](mailto:jakob.kreye@dzne.de); [harald.pruess@dzne.de](mailto:harald.pruess@dzne.de).

## ABSTRACT

The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-neutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from ten COVID-19 patients, we identified 40 strongly neutralizing mAbs. The most potent mAb CV07-209 neutralized authentic SARS-CoV-2 with  $IC_{50}$  of 3.1 ng/ml. Crystal structures of two mAbs in complex with the SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 Å revealed a direct block of ACE2 attachment. Interestingly, some of the near-germline SARS-CoV-2 neutralizing mAbs reacted with mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters from SARS-CoV-2 infection, weight loss and lung pathology. Our results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy.

## INTRODUCTION

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started emerging in humans in late 2019, and rapidly spread to a pandemic with millions of cases worldwide. SARS-CoV-2 infections cause coronavirus disease 2019 (COVID-19) with severe respiratory symptoms, but also pathological inflammation and multi-organ dysfunction, including acute respiratory distress syndrome, cardiovascular events, coagulopathies and neurological symptoms (Helms et al., 2020; Zhou et al., 2020; Zhu et al., 2020). Some aspects of the diverse clinical manifestations may result from a hyperinflammatory response, as suggested by reduced mortality in hospitalized COVID-19 patients under dexamethasone therapy (Horby et al., 2020).

Understanding the immune response to SARS-CoV-2 therefore is of utmost importance. Multiple recombinant SARS-CoV-2 mAbs from convalescent patients have been reported (Brouwer et al., 2020; Cao et al., 2020; Ju et al., 2020; Kreer et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Wec et al., 2020). mAbs targeting the receptor-binding domain (RBD) of the viral spike protein S1 can compete with its binding to human angiotensin converting enzyme 2 (ACE2) and prevent viral entry and subsequent replication (Cao et al., 2020; Ju et al., 2020; Walls et al., 2020). Potent virus neutralizing mAbs that were isolated from diverse variable immunoglobulin (Ig) genes typically carry low levels of somatic hypermutations (SHM). Several of these neutralizing mAbs selected for *in vitro* efficacy showed prophylactic or therapeutic potential in animal models (Cao et al., 2020; Liu et al., 2020; Rogers et al., 2020; Zost et al., 2020). The low number of SHM suggests limited affinity-maturation in germinal centers compatible with an acute infection. Near-germline mAbs usually constitute the first line of defense to pathogens, but carry the risk of self-reactivity to autoantigens (Lerner, 2016; Liao et al., 2011; Zhou et al., 2007). Although critical for the therapeutic use in humans, potential potential tissue-reactivity of near-germline SARS-CoV-2 antibodies has not been examined so far.

Here, we systematically selected 18 strongly neutralizing mAbs out of 598 antibodies from 10 COVID-19 patients by characterization of their biophysical properties, authentic SARS-CoV-2 neutralization, and exclusion of off-target binding to murine tissue. Additionally, we solved two crystal structures of neutralizing mAbs in complex with the RBD, showing antibody engagement with the ACE2 binding site from different approach angles. Finally, we selected mAb CV07-209 by its *in vitro* efficacy and the absence of tissue-reactivity for *in vivo* evaluation. Systemic application of CV07-209 in a hamster model of SARS-CoV-2 infection led to profound reduction of clinical, paraclinical and histopathological COVID-19 pathology, thereby reflecting its potential for translational application in patients with COVID-19.

## RESULTS

### Antibody repertoire analysis of COVID-19 patients

We first characterized the B cell response in COVID-19 using single-cell Ig gene sequencing of human mAbs (Fig. 1A). From ten COVID-19 patients with serum antibodies to the S1 subunit of the SARS-CoV-2 spike protein (Fig. S1, Supplementary Table ST1), we isolated two populations of single cells from peripheral blood mononuclear cells with fluorescence-activated cell sorting (FACS): CD19<sup>+</sup>CD27<sup>+</sup>CD38<sup>+</sup> antibody secreting cells (ASC) reflecting the unbiased humoral immune response and SARS-CoV-2-S1-labeled CD19<sup>+</sup>CD27<sup>+</sup> memory B cells (S1-MBC) for characterization of antigen-specific responses (Fig. S2A and S2B). We obtained 598 functional paired heavy and light chain Ig sequences (Supplementary Table ST2). Of 432 recombinantly expressed mAbs, 122 were reactive to SARS-CoV-2-S1 (S1<sup>+</sup>), with a frequency of 0.0-18.2% (median 7.1%) within ASC and 16.7-84.1% (median 67.1%) within S1-MBC (Fig. 1B and 1C). Binding to S1 did not depend on affinity maturation as measured by the number of SHM (Fig. 1D). Compared to mAbs not reactive to SARS-CoV-2-S1, S1<sup>+</sup> mAbs had less SHM, but equal lengths for both their light and heavy chain complementarity-determining region 3 (CDR3) (Fig. S2C, S2D and S2E). Within the ASC and S1-MBC population, 45.0% and 90.2% of S1<sup>+</sup> mAbs bound the RBD, respectively (Fig. S2F).

S1<sup>+</sup> mAbs were enriched in certain Ig genes including VH1-2, VH3-53, VH3-66, VK1-33 and VL2-14 (Fig. S3). We identified both clonally related antibody clones within patients and public and shared S1<sup>+</sup> clonotypes from multiple patients (Fig. S4). Some public or shared clonotypes had been previously reported, such as IGHV3-53 and IGHV3-66 (Supplementary Table ST3) (Cao et al., 2020; Yuan et al., 2020a), while others were newly identified, such as IGHV3-11 (Fig. S4C).

### Identification and characterization of potent SARS-CoV-2 neutralizing mAbs

We next determined the mAbs with the highest capacity to neutralize SARS-CoV-2 in a plaque reduction neutralization tests (PRNT) using authentic virus (Munich isolate 984) (Wolfel et al., 2020).

Of 86 mAbs strongly binding to RBD, 40 showed virus neutralization with a half-maximal inhibitory concentration ( $IC_{50}$ )  $\leq 250$  ng/ml and were considered neutralizing antibodies (Fig. 1A, Supplementary Table ST2), from which 18 (Top-18) were selected for further characterization (Supplementary Table ST4). The antibodies bound to RBD with a half-maximal effective concentration ( $EC_{50}$ ) of 3.8-14.2 ng/ml (Fig. 1E) and an equilibrium dissociation constant ( $K_D$ ) of 6.0 pM to 1.1 nM (Fig. S5, Supplementary Table ST4), thereby neutralizing SARS-CoV-2 with an  $IC_{50}$  of 3.1-172 ng/ml (Fig. 1F, Supplementary Table ST4). The antibody with the highest affinity, CV07-209, was also the strongest neutralizer (Fig. 1G). We hypothesized that the differences in neutralizing capacity relate to different interactions with the ACE2 binding site. Indeed, the strongest neutralizing mAbs CV07-209 and CV07-250 reduced ACE2 binding to RBD to 12.4% and 58.3%, respectively. Other Top-18 mAbs including CV07-270 interfered only weakly with ACE2 binding (Fig. S6A).

The spike proteins of SARS-CoV-2 and SARS-CoV share more than 70% amino acid sequence identity, whereas sequence identity between SARS-CoV-2 and MERS-CoV and other endemic coronaviruses is significantly lower (Barnes et al., 2020). To analyze potential cross-reactivity of mAbs to other coronaviruses, we tested for binding of the Top-18 mAbs to the RBD of SARS-CoV, MERS-CoV, and the human endemic coronaviruses 229-E, NL63, HKU1 and OC32. CV38-142 detected the RBD of both SARS-CoV-2 and SARS-CoV, whereas no other mAb was cross-reactive to additional coronaviruses (Fig. S7). To further characterize the epitope of neutralizing mAbs, we performed ELISA-based epitope binning experiments using biotinylated antibodies. Co-applications of paired mAbs showed competition of most neutralizing antibodies for RBD binding (Fig. S6B). As an exception, SARS-CoV cross-reactive CV38-142 bound RBD irrespective of the presence of other mAbs, suggesting an independent and conserved target epitope (Fig. S6B).

### **Near-germline SARS-CoV-2 neutralizing antibodies can bind to murine tissue**

Many SARS-CoV-2 neutralizing mAbs carry few SHM or are in germline-configuration (Fig. 1D) (Ju et al., 2020; Kreer et al., 2020). Such antibodies close to germline might be reactive to more than one target (Zhou et al., 2007). Prompted by the abundance of near-germline SARS-CoV-2 antibodies and to exclude potential side-effects of mAb treatment, we next analyzed whether SARS-CoV-2 antibodies can bind to self-antigens.

Therefore, we tested the binding of S1-mAbs to unfixed murine tissues. Surprisingly, four of the Top-18 potent SARS-CoV-2 neutralizing mAbs showed anatomically distinct tissue reactivities (Fig. 2, Supplementary Table ST4). CV07-200 intensively stained brain sections in the hippocampal formation, olfactory bulb, cerebral cortex and basal ganglia (Fig. 2A). CV07-222 also bound to brain tissue, as well as to smooth muscle (Fig. 2B). CV07-255 and CV07-270 were reactive to smooth muscle from sections of lung, heart, kidney and colon, but not liver (Fig. 2C and 2D, Supplementary Table ST4). None of the Top-18 mAbs bound to HEp-2 cells, cardiolipin or beta-2 microglobulin as established polyreactivity-related antigens (Jardine et al., 2016) (Fig. S8).

### **Crystal structures of two mAbs approaching the ACE2 binding site from different angles**

For further characterization using X-ray crystallography, we selected two neutralizing mAbs CV07-250 and CV07-270 based on differences in the number of SHM, extent of ACE2 competition and binding to murine tissue. CV07-250 ( $IC_{50}=3.5$  ng/ml) had 33 SHM (17/16 on heavy and light chain, respectively), strongly reduced ACE2 binding and showed no binding to murine tissue. In contrast, CV07-270 ( $IC_{50}= 82.3$  ng/ml) had only 2 SHM (2/0), did not reduce ACE2 binding in our assay, and showed binding to smooth muscle tissue. Using X-ray crystallography, we determined structures of CV07-250 and CV07-270 in complex with SARS-CoV-2 RBD to resolutions of 2.55 and 2.70 Å, respectively (Fig. 3, Supplementary Tables ST5 and ST6).

The binding mode of CV07-250 to RBD is unusual in that it is dominated by the light chain (Fig. 3A and 3D), whereas in CV07-270, the heavy chain dominates as frequently found in other antibodies



(Fig. 3B and 3E). Upon interaction with the RBD, CV07-250 has a buried surface area (BSA) of 399 Å<sup>2</sup> and 559 Å<sup>2</sup> on the heavy and light chains, respectively, compared to 714 Å<sup>2</sup> and 111 Å<sup>2</sup> in CV07-270. CV07-250 uses CDR H1, H3, L1, L3, and framework region 3 (LFR3) for RBD interaction (Fig. 3D and Fig. 4A, 4B and 4C), whereas CV07-270 interacts with CDR H1, H3, L1, and L2 (Fig. 3E and Fig. 4D, 4E and 4F).

The epitope of CV07-250 completely overlaps with the ACE2 binding site with a similar angle of approach as ACE2 (Fig. 3A, 3C, 4G and 4I). In contrast, the CV07-270 epitope only partially overlaps with the ACE2 binding site and the antibody approaches the RBD from a different angle compared to CV07-250 and ACE2 (Fig. 3B, 3C, 4H, 4I), explaining differences in ACE2 competition. Although CV07-250 and CV07-270 both contact 25 epitope residues, only seven residues are shared (G446/G447/E484/G485/Q493/S494/Q498). Furthermore, CV07-270 binds to a similar epitope as SARS-CoV-2 neutralizing antibody P2B-2F6 (Ju et al., 2020) with a similar angle of approach (Fig. S9). In fact, 18 out of 20 residues in the P2B-2F6 epitope overlap with the CV07-270 epitope, although CV07-270 and P2B-2F6 are encoded by different germline genes for both heavy and light chains.

Interestingly, CV07-250 was isolated 19 days after symptom onset, but already acquired 33 SHM, the highest number among all S1+ MBCs (Fig. S2C). Some non-germline amino acids are not directly involved in RBD binding, including all five SHMs on CDR H2 (Fig. S10). This observation suggests that CV07-250 could have been initially affinity-matured against a different antigen.

### **Prophylactic and therapeutic mAbs in a COVID-19 animal model**

Next, we selected mAb CV07-209 for evaluation of *in vivo* efficacy based on its high capacity to neutralize SARS-CoV-2 and the absence of reactivity to mammalian tissue. We used the hamster model of COVID-19, as it is characterized by rapid weight loss and severe lung pathology

(Osterrieder et al., 2020). In this experimental set-up, hamsters were intranasally infected with authentic SARS-CoV-2. Nine hamsters per group received either a prophylactic application of CV07-209 24 hours before viral challenge, or a therapeutic application of CV07-209 or control antibody mGO53 two hours after viral challenge (Fig. 5A).

Hamsters under control mAb treatment lost  $5.5 \pm 4.4\%$  (mean  $\pm$  SD) of body weight, whereas those that received mAb CV07-209 as a therapeutic or prophylactic single dose gained  $2.2 \pm 3.4\%$  or  $4.8 \pm 3.4\%$  weight after 5 days post-infection (dpi), respectively. Mean body weights gradually converged in the animals followed up until 13 dpi, reflecting the recovery of control-treated hamsters from SARS-CoV-2 infection (Fig. 5B).

To investigate the presence of SARS-CoV-2 in the lungs, we measured functional SARS-CoV-2 particles from lung tissue homogenates. Plaque forming units were below the detection threshold for all animals in the prophylactic and in 2 of 3 in the treatment group at 3 and 5 dpi (Fig. 5C and 5D). qPCR measurements of lung viral genomic RNA copies revealed a 4-5 and 3-4 log decrease at both time points, indicating a dramatic reduction of SARS-CoV-2 virus particles in both the prophylactic and therapeutic group. However, genomic viral RNA copy numbers from nasal washes and laryngeal swabs were similar between all groups (Fig. 5C and 5D).

Additionally, we performed histopathological analyses of infected hamsters. As expected, all lungs from control-treated animals sacrificed at 3 dpi revealed typical histopathological signs of necro-suppurative pneumonia with suppurative bronchitis, necrosis of bronchial epithelial cells and endothelialitis (Fig. 6A). At 5 dpi, control-treated animals showed marked bronchial hyperplasia, severe interstitial pneumonia with marked type II alveolar epithelial cell hyperplasia and endothelialitis (Fig. 6D). In contrast, animals receiving prophylactic treatment with CV07-209 showed no signs of pneumonia, bronchitis, necrosis of bronchial epithelial cells, or endothelialitis at 3 dpi. A mild interstitial pneumonia with mild type II alveolar epithelial cell hyperplasia became apparent 5 dpi. Animals receiving therapeutic treatment with CV07-209 also showed a marked reduction of

histopathological signs of COVID-19 pathology, although at both time points one out of three animals showed mild bronchopulmonary pathology with signs of interstitial pneumonia and endothelialitis. These qualitative findings were mirrored in the reduction of the bronchitis and edema scores (Fig. 6B, 6E and Supplementary Table ST7).

To confirm the absence of viral particles under CV07-209 treatment, we performed *in-situ* hybridization of viral RNA at 3 dpi. No viral RNA was detectable in the prophylactic group, whereas all animals in the control group and one in the therapeutic group revealed intensive staining of viral RNA in proximity of bronchial epithelial cells (Fig. 6C). Taken together, these findings show that systemic application of SARS-CoV-2 neutralizing mAb CV07-209 protects hamsters from COVID-19 lung pathology and weight loss in both the prophylactic and the therapeutic setting.

## DISCUSSION

Our results add several new aspects to the growing knowledge on the humoral immune response in SARS-CoV-2 infections. First, we solved the structures of two neutralizing mAbs binding to the RBD of SARS-CoV-2 at resolutions of 2.55 and 2.70 Å, allowing detailed characterization of the target epitopes and gaining insight into the mechanism of mAbs neutralizing SARS-CoV-2. SARS-CoV-2 mAbs can compete with ACE2 binding and exert neutralizing activity by inhibiting viral particle binding to host cells (Barnes et al., 2020; Brouwer et al., 2020; Cao et al., 2020; Ju et al., 2020; Kreer et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Wec et al., 2020), a key mechanism previously identified in SARS-CoV neutralizing antibodies (Prabakaran et al., 2006; ter Meulen et al., 2006). Steric hindrance of mAbs blocking ACE2 binding to the RBD provides one mechanistic explanation of virus neutralization (Barnes et al., 2020; Cao et al., 2020; Wu et al., 2020). CV07-250 clearly belongs to this category of antibodies, as its epitope lies within the ACE2 binding site and it approaches the RBD from a similar angle as ACE2. In contrast, the epitope of CV07-270 only partially overlaps with the ACE2 binding site and approaches the RBD ridge from a different angle. In line with these findings, competition of CV07-270 with ACE2 binding as detected by ELISA was very weak. Its mechanism of virus neutralization therefore remains elusive. Of note, there have been reports of neutralizing antibodies targeting epitopes distant to the ACE2 binding site (Chi et al., 2020). Future research will need to clarify if additional mechanisms like triggering conformational changes in the spike protein upon antibody binding contribute to virus neutralization, as reported for SARS-CoV (Walls et al., 2019).

Secondly, the majority of our SARS-CoV-2 mAbs are close to germline configuration, supporting previous studies (Kreer et al., 2020; Robbiani et al., 2020). Given the increased probability of auto-reactivity of near-germline antibodies, we examined reactivity with murine tissue and indeed found that a fraction of SARS-CoV-2 neutralizing antibodies also bound to with brain, lung, heart, kidney or gut expressed epitopes. Such reactivity with host antigens should ideally be prevented by

immunological tolerance mechanisms, but complete exclusion of such antibodies would generate “holes” in the antibody repertoire. In fact, HIV utilizes epitopes shared by its envelope and mammalian self-antigens, thus harnessing immunological tolerance to impair anti-HIV antibody responses (Yang et al., 2013) and impeding successful vaccination (Jardine et al., 2016). To defy viral escape in HIV, but similarly COVID-19, anergic strongly self-reactive B cells likely enter germinal centers and undergo clonal redemption to mutate away from self-reactivity, while retaining HIV or SARS-CoV-2 binding (Reed et al., 2016). Interestingly, longitudinal analysis of mAbs in COVID-19 showed that the number of SHM in SARS-CoV-2-neutralizing antibodies only marginally increased over time (Kreer et al., 2020). This finding suggests that the self-reactivity observed in this study may not be limited to mAbs of the early humoral immune response in SARS-CoV-2 infections. Whether self-reactive antibodies could contribute to extra-pulmonary symptoms in COVID-19, awaits further studies and should be closely monitored also in vaccination trials.

Finally, we evaluated in detail the *in vivo* efficacy of the most potent neutralizing antibody CV07-209 in a Syrian hamster model. This model is characterized by a severe phenotype including weight loss and distinct lung pathology. Our results demonstrated that prophylaxis and treatment with a single dose of CV07-209 not only led to clinical improvement as shown by the absence of weight loss, but also to markedly reduced lung pathology. While the findings confirm the efficacy of prophylactic mAb administration reported by other groups in mice, hamsters and rhesus macaques (Cao et al., 2020; Liu et al., 2020; Rogers et al., 2020; Zost et al., 2020), our work is the first to demonstrate the efficacy of post-exposure treatment in hamsters leading to viral clearance, clinical remission and prevention of lung injury. To our knowledge, data on post-exposure treatment so far were restricted to transgenic hACE2 mice (Cao et al., 2020) and a mouse model using adenovector delivery of human ACE2 before viral challenge (Liu et al., 2020). Collectively, our results indicate that mAb treatment can be fine-tuned for exclusion of self-reactivity with mammalian tissues and that mAb administration can also be efficacious after the infection, which will be the prevailing setting in COVID-19 patients.

## REFERENCES

- Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., *et al.* (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* 66, 213-221.
- Bailey, L.J., Sheehy, K.M., Dominik, P.K., Liang, W.G., Rui, H., Clark, M., Jaskolowski, M., Kim, Y., Deneka, D., Tang, W.J., *et al.* (2018). Locking the elbow: improved antibody Fab fragments as chaperones for structure determination. *J Mol Biol* 430, 337-347.
- Barnes, C.O., West, A.P., Jr., Huey-Tubman, K.E., Hoffmann, M.A.G., Sharaf, N.G., Hoffman, P.R., Koranda, N., Gristick, H.B., Gaebler, C., Muecksch, F., *et al.* (2020). Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. *Cell*.
- Brouwer, P.J.M., Caniels, T.G., van der Straten, K., Snitselaar, J.L., Aldon, Y., Bangaru, S., Torres, J.L., Okba, N.M.A., Claireaux, M., Kerster, G., *et al.* (2020). Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. *Science* 369, 643-605.
- Buchholz, U., Muller, M.A., Nitsche, A., Sanewski, A., Wevering, N., Bauer-Balci, T., Bonin, F., Drosten, C., Schweiger, B., Wolff, T., *et al.* (2013). Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. *Euro Surveill* 18, 20406.
- Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., *et al.* (2020). Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. *Cell*.
- Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., *et al.* (2020). A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. *Science* 369, 650-655.
- Corman, V.M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D.K., Bleicker, T., Brunink, S., Schneider, J., Schmidt, M.L., *et al.* (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 25, 2000045.
- Dietert, K., Gutbier, B., Wienhold, S.M., Reppe, K., Jiang, X., Yao, L., Chaput, C., Naujoks, J., Brack, M., Kupke, A., *et al.* (2017). Spectrum of pathogen- and model-specific histopathologies in mouse models of acute pneumonia. *PLoS One* 12, e0188251.
- Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* 60, 2126-2132.
- Erickson, N.A., Gruber, A.D., and Mundhenk, L. (2020). The family of chloride channel regulator, calcium-activated proteins in the feline respiratory tract: a comparative perspective on airway Diseases in man and animal models. *J Comp Pathol* 174, 39-53.
- Gu, Z., Gu, L., Eils, R., Schlesner, M., and Brors, B. (2014). circlize implements and enhances circular visualization in R. *Bioinformatics* 30, 2811-2812.
- Helms, J., Kremer, S., Merdji, H., Clere-Jehl, R., Schenck, M., Kummerlen, C., Collange, O., Boulay, C., Fafi-Kremer, S., Ohana, M., *et al.* (2020). Neurologic features in severe SARS-CoV-2 infection. *N Engl J Med* 382, 2268-2270.
- Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., *et al.* (2020). Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med*.

- Jardine, J.G., Sok, D., Julien, J.P., Briney, B., Sarkar, A., Liang, C.H., Scherer, E.A., Henry Dunand, C.J., Adachi, Y., Diwanji, D., *et al.* (2016). Minimally mutated HIV-1 broadly neutralizing antibodies to guide reductionist vaccine design. *PLoS Pathog* 12, e1005815.
- Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., *et al.* (2020). Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature* 584, 115-119.
- Kornau, H.C., Kreye, J., Stumpf, A., Fukata, Y., Parthier, D., Sammons, R.P., Imbrosci, B., Kurpjuweit, S., Kowski, A.B., Fukata, M., *et al.* (2020). Human cerebrospinal fluid monoclonal LG11 autoantibodies increase neuronal excitability. *Ann Neurol* 87, 405-418.
- Kreer, C., Zehner, M., Weber, T., Ercanoglu, M.S., Gieselmann, L., Rohde, C., Halwe, S., Korenkov, M., Schommers, P., Vanshylla, K., *et al.* (2020). Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients. *Cell*.
- Kreye, J., Wenke, N.K., Chayka, M., Leubner, J., Murugan, R., Maier, N., Jurek, B., Ly, L.T., Brandl, D., Rost, B.R., *et al.* (2016). Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. *Brain* 139, 2641-2652.
- Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., *et al.* (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* 581, 215-220.
- Lerner, R.A. (2016). Combinatorial antibody libraries: new advances, new immunological insights. *Nat Rev Immunol* 16, 498-508.
- Liao, H.X., Chen, X., Munshaw, S., Zhang, R., Marshall, D.J., Vandergrift, N., Whitesides, J.F., Lu, X., Yu, J.S., Hwang, K.K., *et al.* (2011). Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. *J Exp Med* 208, 2237-2249.
- Liu, L., Wang, P., Nair, M.S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J.F., Sahi, V., Figueroa, A., *et al.* (2020). Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike. *Nature*.
- McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read, R.J. (2007). Phaser crystallographic software. *J Appl Crystallogr* 40, 658-674.
- Minor, W., Cymborowski, M., Otwinowski, Z., and Chruszcz, M. (2006). HKL-3000: the integration of data reduction and structure solution—from diffraction images to an initial model in minutes. *Acta Crystallogr D Biol Crystallogr* 62, 859-866.
- Nakamura, T., Karakida, N., Dantsuka, A., Ichii, O., Elewa, Y.H.A., Kon, Y., Nagasaki, K.I., Hattori, H., and Yoshiyasu, T. (2017). Effects of a mixture of medetomidine, midazolam and butorphanol on anesthesia and blood biochemistry and the antagonizing action of atipamezole in hamsters. *J Vet Med Sci* 79, 1230-1235.
- Osterrieder, N., Bertzbach, L.D., Dietert, K., Abdelgawad, A., Vladimirova, D., Kunec, D., Hoffmann, D., Beer, M., Gruber, A.D., and Trimpert, J. (2020). Age-dependent progression of SARS-CoV-2 infection in Syrian hamsters. *Viruses* 12, E779.
- Prabakaran, P., Gan, J., Feng, Y., Zhu, Z., Choudhry, V., Xiao, X., Ji, X., and Dimitrov, D.S. (2006). Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. *J Biol Chem* 281, 15829-15836.
- Reed, J.H., Jackson, J., Christ, D., and Goodnow, C.C. (2016). Clonal redemption of autoantibodies by somatic hypermutation away from self-reactivity during human immunization. *J Exp Med* 213, 1255-1265.
- Reincke, M., Prüss, H., and Kreye, J. (2019). Brain Antibody Sequence Evaluation (BASE): an easy-to-use software for complete data analysis in single cell immunoglobulin cloning (bioRxiv).

Robbiani, D.F., Gaebler, C., Muecksch, F., Lorenzi, J.C.C., Wang, Z., Cho, A., Agudelo, M., Barnes, C.O., Gazumyan, A., Finkin, S., *et al.* (2020). Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature*.

Rogers, T.F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.T., Limbo, O., Smith, C., Song, G., Woehl, J., *et al.* (2020). Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science*.

Rohrbeck, A., Schroder, A., Hagemann, S., Pich, A., Holtje, M., Ahnert-Hilger, G., and Just, I. (2014). Vimentin mediates uptake of C3 exoenzyme. *PLoS One* 9, e101071.

Schritt, D., Li, S., Rozewicki, J., Katoh, K., Yamashita, K., Volkmuth, W., Cavet, G., and Standley, D.M. (2019). Repertoire Builder: high-throughput structural modeling of B and T cell receptors. *Mol Syst Des Eng* 4, 761-768.

ter Meulen, J., van den Brink, E.N., Poon, L.L., Marissen, W.E., Leung, C.S., Cox, F., Cheung, C.Y., Bakker, A.Q., Bogaards, J.A., van Deventer, E., *et al.* (2006). Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. *PLoS Med* 3, e237.

Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., and Veesler, D. (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* 181, 281-292 e286.

Walls, A.C., Xiong, X., Park, Y.J., Tortorici, M.A., Snijder, J., Quispe, J., Cameroni, E., Gopal, R., Dai, M., Lanzavecchia, A., *et al.* (2019). Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. *Cell* 176, 1026-1039 e1015.

Wec, A.Z., Wrapp, D., Herbert, A.S., Maurer, D.P., Haslwanter, D., Sakharkar, M., Jangra, R.K., Dieterle, M.E., Lilov, A., Huang, D., *et al.* (2020). Broad neutralization of SARS-related viruses by human monoclonal antibodies. *Science* 369, 731-736.

Wolfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Muller, M.A., Niemeyer, D., Jones, T.C., Vollmar, P., Rothe, C., *et al.* (2020). Virological assessment of hospitalized patients with COVID-2019. *Nature* 581, 465-469.

Wu, Y., Wang, F., Shen, C., Peng, W., Li, D., Zhao, C., Li, Z., Li, S., Bi, Y., Yang, Y., *et al.* (2020). A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. *Science* 368, 1274-1278.

Yang, G., Holl, T.M., Liu, Y., Li, Y., Lu, X., Nicely, N.I., Kepler, T.B., Alam, S.M., Liao, H.X., Cain, D.W., *et al.* (2013). Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. *J Exp Med* 210, 241-256.

Yuan, M., Liu, H., Wu, N.C., Lee, C.-C.D., Zhu, X., Zhao, F., Huang, D., Yu, W., Hua, Y., Tien, H., *et al.* (2020a). Structural basis of a shared antibody response to SARS-CoV-2. *Science*

Yuan, M., Wu, N.C., Zhu, X., Lee, C.D., So, R.T.Y., Lv, H., Mok, C.K.P., and Wilson, I.A. (2020b). A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. *Science* 368, 630-633.

Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., *et al.* (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 579, 270-273.

Zhou, Z.H., Tzioufas, A.G., and Notkins, A.L. (2007). Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. *J Autoimmun* 29, 219-228.

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., *et al.* (2020). A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med* 382, 727-733.

Zivcec, M., Safronetz, D., Haddock, E., Feldmann, H., and Ebihara, H. (2011). Validation of assays to monitor immune responses in the Syrian golden hamster (*Mesocricetus auratus*). *J Immunol Methods* 368, 24-35.



Zost, S.J., Gilchuk, P., Case, J.B., Binshtein, E., Chen, R.E., Nkolola, J.P., Schafer, A., Reidy, J.X., Trivette, A., Nargi, R.S., *et al.* (2020). Potently neutralizing and protective human antibodies against SARS-CoV-2. *Nature*.

## Acknowledgments

We thank Stefanie Bandura, Matthias Sillmann and Doreen Brandl for excellent technical assistance, Christian Meisel for performing a cardiolipin ELISA and Martin Barner for assistance in generating the circos plot in Fig. S4B. We acknowledge BIAFFIN GmbH & Co KG (Kassel, Germany) for performance of SPR measurements and Dr. Désirée Kunkel from Flow & Mass Cytometry Core Facility at Charité - Universitätsmedizin Berlin for support with single cell sorting.

## Funding

SMR is participant in the BIH-Charité Junior Clinician Scientist Program funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health. Work at Scripps was supported by NIH K99 AI139445 (NCW) and the Bill and Melinda Gates Foundation OPP1170236 (IAW). Use of the SSRL, SLAC National Accelerator Laboratory, is supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract No. DE-AC02–76SF00515. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research, and by the National Institutes of Health, National Institute of General Medical Sciences (including P41GM103393). This work was supported by COVID-19 grants from Freie Universität Berlin and Berlin University Alliance to NO and LES; and by the German Research Foundation (DFG) to ADG, SH, NS, MW and LES (grant SFB-TR84), to ME and DS (EXC2049) and to HP (grant numbers PR 1274/2-1, PR 1274/3-1, PR 1274/5-1); and by the Helmholtz Association to HCK (grant ExNet0009) and to HP (grant HIL-A03); and by the Federal Ministry of Education and Research to HP (Connect-Generate, 01GM1908D) and MW, ACH, SH, NS and LES (PROVID, 01KI20160A and SYMPATH, 01ZX1906A).

## **Author Contributions**

JK, SMR, HCK, VMC, JT, KD, HL, MY, NCW, IAW, HP designed the study. SMR, LS, JH, SH, MW, NS, FK, CF, DW and LES collected patient material and led the clinical study PA-COVID-19. JK, SMR, HCK, ESS, VMC, HL, MY, NCW, XZ, CCDL, JT, MH, KD, LS, NvW, SvH, MAH, JH, AA, LDB, DV, LYL, PCB, AH, KS, LMJ, AR, MLS, TS and DW carried out experiments. JK, SMR, HCK, ESS, VMC, HL, MY, NCW, JT, MH, LDB, KD, ADG, ME, DS, ADG, MAM, CD, NO, IAW, HP analyzed and interpreted acquired data. JK, SMR and HP drafted the manuscript. All authors critically revised and approved the submitted version.

## **Competing interests**

Related to this work the German Center for Neurodegenerative Diseases (DZNE) and the Charité - Universitätsmedizin have filed a patent application on which JK, SMR, HCK, ESS, VMC, MAM, DW, LES and HP are named as inventors.


## **Materials availability**

Antibodies will be made available by the corresponding authors upon request under a Material Transfer Agreement (MTA) for non-commercial usage.

## **Data and Code Availability**

X-ray coordinates and structure factors are deposited at the RCSB Protein Data Bank under accession codes 6XKQ and 6XKP. The raw sequencing data associated with this manuscript will be deposited together with the analysis using BASE on Code Ocean upon publication and will be shared upon request during review. The software used for Ig sequence analysis is available on <https://github.com/automatedSequencing/BASE>.


## FIGURES



**Fig.1 | Identification and characterization of potent SARS-CoV-2 neutralizing mAbs.**


(A) Diagram depicting the strategy for isolation of 18 potentially neutralizing mAbs (Top-18). (B) Normalized binding to S1 of SARS-CoV-2 for mAbs isolated from antibody secreting cells (▼; blue = S1-binding, grey = not S1-binding). (OD=optical density in ELISA) (C) Normalized binding to S1 of SARS-CoV-2 for mAbs isolated from S1-stained memory B cells (▲; colors like in (B)) (D) S1-binding plotted against the number of somatic hypermutations (SHM) for all S1-reactive mAbs.

(E) Concentration-dependent binding of Top-18 SARS-CoV-2 mAbs to the RBD of S1 (mean±SD from two wells of one experiment). (F) Concentration-dependent neutralization of authentic SARS-CoV-2 plaque formation by Top-18 mAbs (mean±SD from two independent measurements). (G) Affinity of mAbs to RBDs ( $K_D$  determined by surface plasmon resonance) plotted against  $IC_{50}$  of authentic SARS-CoV-2 neutralization.




**Fig. 2 | SARS-CoV-2 neutralizing antibodies can bind to murine tissue.**

Immunofluorescence staining of SARS-CoV-2 mAbs (green) on murine organ sections showed specific binding to distinct anatomical structures, including (A) staining of hippocampal neuropil with CV07-200 (cell nuclei depicted in blue), (B) staining of bronchial walls with CV07-222, (C) staining of vascular walls with CV07-255, and (D) staining of intestinal walls with CV07-270. Smooth muscle tissue in (B-D) was co-stained with a commercial smooth muscle actin antibody (red).




**Fig. 3 | Crystal structures of mAbs in complex with SARS-CoV-2 RBD.**

(A) CV07-250 (cyan) in complex with RBD (white). (B) CV07-270 (pink) in complex with RBD (white). (C) Human ACE2 with SARS-CoV-2 RBD (PDB 6M0J) (Lan et al., 2020). (D-E) Epitopes of (D) CV07-250 and (E) CV07-270. Epitope residues contacting the heavy chain are in orange and the light chain in yellow. CDR loops and framework region that contact the RBD are labeled. (F) ACE2-binding residues on the RBD (blue) in the same view as (D) and (E). The ACE2 interacting region is shown in green within a semi-transparent cartoon representation.




**Fig. 4 | Interactions and angle of approach at the RBD-antibody interface.**

(A-C) Key interactions between CV07-250 (cyan) and RBD (white) are highlighted. (A) CDR H3 of CV07-250 forms a hydrogen-bond network with RBD Y489 and N487. (B) V<sub>H</sub> Y100b (CDR H3), V<sub>L</sub> F32 (CDR L1), and V<sub>L</sub> Y91 (CDR L3) of CV07-250 form a hydrophobic aromatic patch for interaction with RBD L455 and F456. (C) The side chain of V<sub>L</sub> S67 and backbone amide of V<sub>L</sub> G68 from FR3 is engaged in a hydrogen-bond network with RBD G446 and Y449. (D-F) Interactions between CV07-270 (cyan) and RBD (white) are illustrated. (D) Residues in CDR H1 of CV07-270 participate in an electrostatic and hydrogen-bond network with RBD R346 and K444. (E) V<sub>H</sub> W100h and V<sub>H</sub> W100k on CDR H3 of CV07-270 make  $\pi$ - $\pi$  stacking interactions with Y449. V<sub>H</sub> W100k is also stabilized by a  $\pi$ - $\pi$  stacking interaction with V<sub>L</sub> Y49. (F) V<sub>H</sub> R100g on CDR H3 of CV07-270 forms an electrostatic interaction with RBD E484 as well as a  $\pi$ -cation interaction with RBD F490. Oxygen atoms are in red, and nitrogen atoms in blue. Hydrogen bonds are represented by dashed lines. (G-I) Zoomed-in views of the different RBD ridge interactions with (G) CV07-250, (H) CV07-270, and (I) ACE2 (PDB 6M0J) (Lan et al., 2020). The ACE2-binding ridge in the RBD is represented by a backbone ribbon trace in red.



**Fig. 5 | Prophylactic and therapeutic application of mAb CV07-209 in a COVID-19 hamster model.**

(A) Schematic overview of the animal experiment. (B) Body weight of hamsters after virus challenge and prophylactic (pink) or therapeutic (blue) application of SARS-CoV-2 neutralizing mAb CV07-209 or control antibody (mean±SEM from n=9 animals per group from day -1 to 3, n=6 from days 4 to 5; n=3 from days 6 to 13; mixed-effects model with posthoc Dunnett's multiple tests in comparison to control group; significance levels shown as \* (p<0.05), \*\* (p<0.01), \*\*\* (p<0.001), \*\*\*\* (p<0.0001), or not shown when not significant). (C-D) Quantification of plaque forming units (PFU) from lung homogenates and quantification of SARS-CoV-2 RNA copies per 10<sup>5</sup> cellular transcripts from samples and timepoints as indicated. PFU were set to 5 when not detected, RNA copies below 1 were set to 1. Bars indicate mean. Dotted lines represent detection threshold.



**Fig. 6 | Histopathological analysis of hamsters after SARS-CoV-2 infection.**

(A) Histopathology of representative haematoxylin and eosin stained, paraffin-embedded bronchi with inserted epithelium (upper row) and lung parenchyma with inserted blood vessels (lower row) at 3 dpi. Severe suppurative bronchitis with immune cell infiltration (hash) is apparent only in the control-treated animals with necrosis of bronchial epithelial cells (diagonal arrows). Necro-suppurative interstitial pneumonia (upward arrows) with endothelialitis (downward arrows) is prominent in control-treated animals. Scale bars: 200  $\mu$ m in bronchus overview, 50  $\mu$ m in all others. (B) Bronchitis and edema score at 3 dpi. (C) Detection of viral RNA (red) using *in situ* hybridization of representative bronchial epithelium present only in the control group. Scale bars: 50  $\mu$ m. (D) Histopathology of representative lung sections from comparable areas as in (A) at 5 dpi. Staining of bronchi of control-treated animals showed a marked bronchial hyperplasia with hyperplasia of epithelial cells (diagonal arrow) and still existing bronchitis (hash), absent in all prophylactically treated and in 2/3 therapeutically treated animals (upper row). Lung parenchyma staining of control-treated animals showed severe interstitial pneumonia with marked type II alveolar epithelial cell hyperplasia and endothelialitis (insets, downward arrows). Compared to control-treated animals, prophylactically treated animals showed only mild signs of interstitial pneumonia with mild type II alveolar epithelial cell hyperplasia (upward arrow), whereas therapeutically treated animals showed a more heterogeneous picture with 1/3 showing no signs of lung pathology, 1/3 animal showing only mild signs of interstitial pneumonia, and 1/3 animal showing a moderate multifocal interstitial pneumonia. Scale bars: 200  $\mu$ m in bronchus overview, 50  $\mu$ m in all others. (E) Bronchitis and edema score at 5 dpi.



## **MATERIALS AND METHODS**

### **SARS-CoV-2-infected individuals and sample collection**

The patients have given written informed consent and analyses were approved by the Institutional Review Board of Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin. All patients in this study were tested positive for SARS-CoV-2 infection by RT-PCR. Patient characteristics are described in Supplementary Table ST1.

### **PBMC collection and FACS staining**

Recombinant SARS-CoV-2-S1 protein produced in HEK cells (Creative Diagnostics, DAGC091) was covalently labeled using CruzFluor647 (Santa Cruz Biotechnology, sc-362620) according to the manufacturer's instructions.

Using fluorescence-activated cell sorting we sorted viable single cells from freshly isolated peripheral blood mononuclear cells (PBMCs as 7AAD<sup>-</sup>CD19<sup>+</sup>CD27<sup>+</sup>CD38<sup>+</sup> antibody-secreting cells (ASCs) or SARS-CoV2-S1-enriched 7AAD<sup>-</sup>CD19<sup>+</sup>CD27<sup>+</sup> memory B cells (MBCs) into 96-well PCR plates. Staining was performed on ice for 25 minutes in PBS with 2 % FCS using the following antibodies: 7-AAD 1:400 (Thermo Fisher Scientific), CD19-BV786 1:20 (clone SJ25C1, BD Biosciences, 563326), CD27-PE 1:5 (clone M-T271, BD Biosciences, 555441), CD38-FITC 1:5 (clone HIT2, BD Biosciences, 560982), and SARS-CoV-S1-CF647 at 1 µg/ml for patients CV07, CV38, CV23, CV24, CV 38, CV48, CV-X1, CV-X2 and CV01 (second time point, fig. S1). The first patients (CV01 (first time point), CV03, and CV05) were stained with a divergent set of antibodies: CD19-PE 1:50 (clone HIB19, BioLegend, 302207), CD38-PEcy7 1:50 (clone HIT2, BioLegend, 303505), CD27-APC 1:50 (clone O323, BioLegend, 302809) and DAPI as viability dye.

### **Generation of recombinant human monoclonal antibodies**

Monoclonal antibodies were generated following our established protocols (Kornau et al., 2020; Kreye et al., 2016) with modifications as mentioned. We used a nested PCR strategy to amplify variable domains of immunoglobulin heavy and light chain genes from single cell cDNA and analyzed sequences with aBASE module of customized Brain Antibody Sequence Evaluation (BASE) software (Reincke et al., 2019). Pairs of functional Ig genes were PCR-amplified using specific primers with Q5 Polymerase (NEB). PCR-product and linearized vector were assembled using Gibson cloning with HiFi DNA Assembly Master Mix (NEB). Cloning was considered successful when sequence identity >99.5% was given, verified by the cBASE module of BASE software. For mAb expression, human embryonic kidney cells (HEK293T) were transiently transfected with matching Ig heavy and light chains. Three days later mAb containing cell culture supernatant was harvested. Ig concentrations were determined and used for reactivity and neutralization screening, if Ig concentration was above 1 µg/ml. For biophysical characterization assays and *in vivo* experiments, supernatants were purified using Protein G Sepharose beads (GE Healthcare), dialyzed against PBS and sterile-filtered using 0.2 µm filter units (GE Healthcare). For *in vivo* experiments, mAbs were concentrated using Pierce™ 3K Protein Concentrator PES (Thermo Scientific).

### **SARS-CoV-2-S1 ELISA**

Screening for SARS-CoV-2-specific mAbs was done by using anti-SARS-CoV-2-S1 IgG ELISAs (EUROIMMUN Medizinische Labordiagnostika AG) according to the manufacturer's protocol. mAb containing cell culture supernatants were pre-diluted 1:5, patient sera 1:100. Optical density (OD) ratios were calculated by dividing the OD at 450 nm by the OD of the calibrator included in the kit. OD ratios of 0.5 were considered reactive.

### **RBD ELISA**

Binding to the receptor-binding domain (RBD) of S1 was tested in an ELISA. To this end, a fusion protein (RBD-Fc) of the signal peptide of the NMDA receptor subunit GluN1, the RBD-SD1 part of

SARS-CoV2-S1 (amino acids 319-591) and the constant region of rabbit IgG1 heavy chain (Fc) was expressed in HEK293T cells and immobilized onto 96-well plates from cell culture supernatant via anti-rabbit IgG (Dianova, 111-035-045) antibodies. Then, human mAbs were applied and detected using horseradish peroxidase (HRP)-conjugated anti-human IgG (Dianova, 109-035-088) and the HRP substrate 1-step Ultra TMB (Thermo Fisher Scientific, Waltham, MA). All S1+ mAbs were screened at a human IgG concentration of 10 ng/ml to detect strong RBD binders and the ones negative at this concentration were re-evaluated for RBD reactivity using a 1:5 dilution of the cell culture supernatants. To test for specificity within the coronavirus family, we expressed and immobilized Fc fusion proteins of the RBD-SD1 regions of MERS-CoV, SARS-CoV and the endemic human coronaviruses HCoV-229-E, HCoV-NL63, HCoV-HKU1, and HCoV-229E and applied mAbs at 1 µg/ml. The presence of immobilized antigens was confirmed by incubation with HRP-conjugated anti-rabbit IgG (Dianova). Assays for concentration-dependent RBD binding (Fig. 1E) were developed using 1-step Slow TMB (Thermo Fisher Scientific). EC<sub>50</sub> was determined from non-linear regression models using Graph Pad Prism 8.

To evaluate the ability of mAbs to interfere with the binding of ACE2 to SARS-CoV-2 RBD, we expressed ACE2-HA, a fusion protein of the extracellular region of human ACE2 (amino acids 1-615) followed by a His-tag and a hemagglutinin (HA)-tag in HEK293T cells and applied it in a modified RBD-ELISA. Captured RBD-Fc was incubated with mAbs at 0.5 µg/ml for 15 minutes and subsequently with ACE2-HA-containing cell culture supernatant for 1 h. ACE2-HA binding was detected using anti-HA antibody HA.11 (clone 16B12, BioLegend, San Diego, CA, MMS-101P), HRP-conjugated anti-mouse IgG (Dianova, 115-035-146) and 1-step UltraTMB.

For experiments regarding the competition between mAbs for RBD binding, purified monoclonal antibodies were biotinylated using EZ-Link Sulfo-NHS-Biotin (Thermo Fisher) according to the manufacturer's instructions. Briefly, 50-200 µg of purified antibody were incubated with 200-fold molar excess Sulfo-NHS-Biotin for 30 minutes at room temperature. Excess Sulfo-NHS-Biotin was removed by dialysis for 16 hours. Recovery rate of IgG ranged from 60-100%. RBD-Fc captured on ELISA

plates was incubated with mAbs at 10 µg/ml for 15 minutes. Then, one volume of biotinylated mcAbs at 100 ng/ml was added and the mixture incubated for additional 15 minutes, followed by detection using HRP-conjugated streptavidin (Roche Diagnostics) and 1-step Ultra TMB. Background by the HRP-conjugated detection antibodies alone was subtracted from all absorbance values.

### **Circos plot of public clonotypes**

Antibodies which share same V and J gene on both Ig heavy and light chain are considered to be one clonotype. Such clonotypes are considered *public* if they are identified in different patients. After identification of public clonotypes, they were plotted in a Circos plot using the R package circlize (Gu et al., 2014).

### **Identification of 18 strongly neutralizing antibodies**

To identify the most potent SARS-CoV-2 neutralizing mAb, all 122 S1-reactive mAbs were screened for binding to RBD. 86 were defined as strongly binding to RBD (defined as detectable binding at 10 ng/ml in an RBD ELISA) and then assessed for neutralization of authentic SARS-CoV-2 at 25 and 250 ng/ml using mAb-containing cell culture supernatants. Antibodies were further selected (i) as the strongest neutralizing mAb of the respective donor and / or (ii) with an estimated IC<sub>50</sub> of 25 ng/ml or below and / or (iii) with an estimated IC<sub>90</sub> of 250 ng/ml or below. These were defined as the 18 most potent antibodies (Top-18) and expressed as purified antibodies for detailed biophysical characterization.

### **Surface plasmon resonance measurements**

The antigen (SARS-CoV-2 S protein-RBD-mFc, Accrobiosystems) was reversibly immobilized on a C1 sensor chip via anti-mouse IgG. Purified mAbs were injected at different concentrations in a buffer consisting of 10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% Tween 20. CV-X1-126 and CV38-139 were analyzed in a buffer containing 400 mM NaCl as there was a slight upward drift at the

beginning of the dissociation phase due to non-specific binding of to the reference flow. Multi-cycle-kinetics analyses were performed in duplicates except for non-neutralizing CV03-191.  $K_a$ ,  $K_d$  and  $K_D$ -values were determined using a monovalent analyte model. Recordings were performed on a Biacore T200 instrument at 25°C.

### **Plaque reduction neutralization test**

To detect neutralizing activity of SARS-CoV-2-specific mAbs, plaque reduction neutralization tests (PRNT) were done as described before (Wolfel et al., 2020). Briefly, Vero E6 cells ( $1.6 \times 10^5$  cells/well) were seeded in 24-well plates and incubated overnight. For each dilution step, mAbs were diluted in OptiPro and mixed 1:1 with 200  $\mu$ l virus (Munich isolate 984) (Wolfel et al., 2020) solution containing 100 plaque forming units. The 400  $\mu$ l mAb-virus solution was vortexed gently and incubated at 37°C for 1 hour. Each 24-well was incubated with 200  $\mu$ l mAb-virus solution. After 1 hour at 37°, the supernatants were discarded and cells were washed once with PBS and supplemented with 1.2% Avicel solution in DMEM. After 3 days at 37°C, the supernatants were removed and the 24-well plates were fixed and inactivated using a 6% formaldehyde/PBS solution and stained with crystal violet. All dilutions were tested in duplicates. For PRNT-screening mAb dilutions of 25 and 250 ng of IgG/ml were assessed.  $IC_{50}$  was determined from non-linear regression models using Graph Pad Prism 8.

### **Immunocytochemistry**

Recombinant spike protein-based immunofluorescence assays were done as previously described (Buchholz et al., 2013; Corman et al., 2020; Wolfel et al., 2020). Briefly, VeroB4 cells were transfected with previously described pCG1 plasmids encoding SARS-CoV-2, MERS-CoV, HCoV-NL63, -229E, -OC43, and -HKU1 spike proteins (Buchholz et al., 2013). For transfection, Fugene HD (Roche) was used in a Fugene to DNA ratio of 3:1. After 24 hours, transfected as well as untransfected VeroB4 cells were harvested and resuspended in DMEM/10% FCS to achieve a cell density of  $2.5 \times 10^5$  cells/ml each. Transfected and untransfected VeroB4 cells were mixed 1:1 and 50

$\mu$ l of the cell suspension was applied to each incubation field of a multitest cover slide (Dunn Labortechnik). The multitest cover slides were incubated for 6 hours before they were washed with PBS and fixed with ice-cold acetone/methanol (ratio 1:1) for 10 minutes. For the immunofluorescence test, the incubation fields were blocked with 5% non-fat dry milk in PBS/0.2% Tween for 60 minutes. Purified mAbs were diluted in EUROIMMUN sample buffer to a concentration of 5  $\mu$ g/ml and 30  $\mu$ l of the dilution was applied per incubation field. After 1 hour at room temperature, cover slides were washed 3 times for 5 minutes with PBS/0.2% Tween. Secondary detection was done using a 1:200 dilution of a goat-anti human IgG-Alexa488 (Dianova). After 30 minutes at room temperature, slides were washed 3 times for 5 minutes and rinsed with water. Slides were mounted using DAPI prolonged mounting medium (FisherScientific).

### **Crystal structure determination of Fab-RBD complexes**

The receptor binding domain (RBD; residues 319-541) of the SARS-CoV-2 spike (S) protein was expressed in High Five cells and purified using affinity and size exclusion chromatography as described previously (Yuan et al., 2020b). Residues in the elbow region of CV07-250 (112SSASTKG118) were mutated to 112FNQIKP117 to reduce elbow flexibility and facilitate crystal packing (Bailey et al., 2018). CV07-250 and CV07-270 Fabs were expressed in ExpiCHO cells and purified using affinity and size exclusion chromatography. The Fab/RBD complexes were formed by mixing the two components in an equimolar ratio and incubating overnight at 4°C before setting-up crystal trials. The complexes of CV07-250/RBD and CV07-270/RBD were screened for crystallization at 20.0 and 12.0 mg/ml, respectively, using 384 conditions of the JCSG Core Suite (Qiagen) on our robotic CrystalMation system (Rigaku) at The Scripps Research Institute. Crystals appeared after day 3, were harvested after day 7, and then flash-cooled in liquid nitrogen for X-ray diffraction experiments. Diffraction data were collected at cryogenic temperature (100 K) at Stanford Synchrotron Radiation Lightsource (SSRL) on the newly constructed Scripps/Stanford beamline 12-1 with a beam wavelength of 0.97946 Å and processed with HKL3000 (Minor et al., 2006). Diffraction

data were collected from crystals grown in conditions: 0.085 M HEPES pH 7.5, 10% (v/v) ethylene glycol, 15% (v/v) glycerol, 8.5% (v/v) 2-propanol, 17% (w/v) polyethylene glycol 4000 for the CV07-250/RBD complex and 0.1 M sodium cacodylate pH 6.5, 0.2 M sodium chloride, 2 M ammonium sulfate, 15% (v/v) ethylene glycol for the CV07-270/RBD complex. The X-ray structures were solved by molecular replacement (MR) using PHASER (McCoy et al., 2007) with MR models for the RBD and CV07-270 Fab from PDB 6W41 (Yuan et al., 2020b) and 4FQH, respectively. The MR model for CV07-250 Fab was generated using Repertoire Builder (Schritt et al., 2019). Iterative model building and refinement were carried out in COOT (Emsley and Cowtan, 2004) and PHENIX (Adams et al., 2010), respectively. In the CV07-250 + RBD structure, residues 319-337, 357-366, 371-374, 383-396, 516-541 were not modeled due to paucity of electron density. The N and C terminal regions are normally disordered in the SARS CoV-2 RBD structures. These flexible regions are not involved in any other contacts, including crystal lattice contacts, and are on the opposite side of the RBD to the epitope, which is well ordered. In the CV07-270 + RBD structure, Fab residues in a region of the heavy-chain constant domain also have greater mobility as commonly found in Fabs. Likewise, the N and C-terminal residues of 319-333 and 528-541 in both RBD molecules of the asymmetric unit are disordered. Epitope and paratope residues, as well as their interactions, were identified by accessing PDBePISA at the European Bioinformatics Institute ([https://www.ebi.ac.uk/pdbe/prot\\_int/pistart.html](https://www.ebi.ac.uk/pdbe/prot_int/pistart.html)).

### **Murine tissue reactivity screening**

Preparations of brain, lung, heart, liver, kidney and gut from 8-12 weeks old C57BL/6J mice were frozen in -50°C 2-methylbutane, cut on a cryostat in 20 µm sections and mounted on glass slides. For tissue reactivity screening according to established protocols (Kreye 2016 Brain), thawed unfixed tissue slices were rinsed with PBS then blocked with blocking solution (PBS supplemented with 2% Bovine Serum Albumin (Roth) and 5% Normal Goat Serum (Abcam)) for 1 hour at room temperature before incubation of mAbs at 5 µg/ml overnight at 4°C. After three PBS washing steps, goat anti-human IgG-Alexa Fluor 488 (Dianova, 109-545-003) diluted in blocking solution was applied for 2

hours at room temperature before additional three washes and mounting using DAPI-containing Fluoroshield. Staining was examined under an inverted fluorescence microscope (Olympus CKX41, Leica DMI6000) or confocal device (Leica TCS SL). For co-staining, tissue was processed as above, but sections were fixed with 4% PFA in PBS for 10 minutes at room temperature before blocking. For co-staining, the following antibodies were used: mouse Smooth Muscle Actin (clone 1A4, Agilent, 172 003), goat anti-mouse IgG-Alexa Fluor 594 (Dianova, 115-585-003). For nuclei staining DRAQ5™ (abcam, ab108410) was used.

### **HEp2 cell assay**

HEp-2 cell reactivity was investigated using the NOVA Lite HEp-2 ANA Kit (Inova Diagnostics) according to the manufacturer's instructions using mAb containing culture supernatant (screening of all S1+ mAbs) or purified mAbs at 50 µg/ml (polyreactivity testing of CV07-200, CV07-209, CV07-222, CV07-255, CV07-270 and CV38-148) and examined under an inverted fluorescence microscope.

### **Polyreactivity screening ELISA**

Purified mAbs were screened for reactivity against cardiolipin and beta-2 microglobulin at 50 µg/ml using routine laboratory ELISAs kindly performed by Christian Meisel (Labor Berlin).

### **Hamster model of SARS-CoV-2 infection**

The animal experiment was approved by the Landesamt für Gesundheit und Soziales in Berlin, Germany (approval number 0086/20) and performed in compliance with relevant national and international guidelines for care and humane use of animals. In vitro and animal work was conducted under appropriate biosafety precautions in a BSL-3 facility at the Institute of Virology, Freie Universität Berlin, Germany. Twenty-seven six-week old female and male golden Syrian hamsters (*Mesocricetus auratus*; outbred hamster strain RjHan:AURA, Janvier Labs) were kept in groups of 3 animals in enriched, individually ventilated cages. The animals had ad libitum access to food and



water and were allowed to acclimate to these conditions for seven days prior to prophylactic treatment and infection. Cage temperatures and relative humidity were recorded daily and ranged from 22-24°C and 40-55%, respectively.

Virus stocks for animal experiments were prepared from the previously published SARS-CoV-2 München isolate (Wolfel et al., 2020). Viruses were propagated on Vero E6 cells (ATCC CRL-1586) in minimal essential medium (MEM; PAN Biotech) supplemented with 10% fetal bovine serum (PAN Biotech) 100 IU/ml Penicillin G and 100 µg/ml Streptomycin (Carl Roth). Stocks were stored at -80°C prior to experimental infections.

For the SARS-CoV-2 challenge experiments, hamsters were randomly distributed into three groups: In the first group (prophylaxis group), animals received an intraperitoneal (i.p.) injection of 18 mg per kg bodyweight of SARS-CoV-2 neutralizing mAb CV07-209 24 hours prior to infection. In the second and third group (treatment and control group, respectively), animals were given the identical mAb amount two hours after infection, either with 18 mg/kg of CV07-209 (treatment group) or with 20 mg/kg of non-reactive isotype-matched mGO53 (control group). Hamsters were infected intranasally with SARS-CoV-2 infected as previously described (Osterrieder et al., 2020).

On days 2, 5 and 13 post infection, three hamsters of each group were euthanized by exsanguination under general anesthesia as described (Nakamura et al., 2017). Nasal washes, tracheal swabs, and lungs (left and right) were collected for histopathological examinations and/or virus titrations and RT-qPCR. Body weights were recorded daily and clinical signs of all animals were monitored twice daily throughout the experiment.

### **Histopathology and *in situ* hybridization**

For histopathological examination and *in situ* hybridization (ISH) of lung tissues, the left lung lobe was carefully removed and immersed in fixative solution (4% formalin, pH 7.0) for 48 hours. Lungs were then embedded in paraffin and cut in 2 µm sections. For histopathology, slides were stained with

hematoxylin and eosin (HE) followed by blinded microscopic evaluation by board-certified veterinary pathologists as previously described (Dietert et al., 2017; Osterrieder et al., 2020). The following parameters were evaluated to assess three different scores: (1) the bronchitis score that includes severity of bronchial inflammation and epithelial cell necrosis of bronchi; (2) the regeneration score combining the presence of hyperplasia of bronchial epithelial cells and alveolar type II epithelial cells; and (3) the edema score including alveolar and perivascular edema.

ISH was performed as reported previously (Erickson et al., 2020; Osterrieder et al., 2020) using the ViewRNA™ ISH Tissue Assay Kit (Invitrogen by Thermo Fisher Scientific) following the manufacturer's instructions with minor adjustments. Probes for the detection of the Nucleoprotein (N) gene RNA of SARS-CoV-2 (NCBI database NC\_045512.2, nucleotides 28,274 to 9,533, assay ID: VPNKRHM), and the murine housekeeping gene eukaryotic translation elongation factor-1 $\alpha$  (EF1 $\alpha$ ; assay ID: VB1-14428-VT, Affymetrix, Inc.), that shares 95% sequence identity with the Syrian hamster, were designed. Lung sections (2  $\mu$ m thickness) on adhesive glass slides were dewaxed in xylol and dehydrated in ethanol. Tissues were incubated at 95°C for 10 minutes with subsequent protease digestion for 20 minutes. Sections were fixed with 4% paraformaldehyde in PBS (Alfa Aesar, Thermo Fisher) and hybridized with the probes. Amplifier and label probe hybridizations were performed according to the manufacturer's instructions using fast red as the chromogen, followed by counterstaining with hematoxylin for 45 s, washing in tap water for 5 minutes, and mounting with Roti®-Mount Fluor-Care DAPI (4, 6-diaminidino-2-phenylindole; Carl Roth). An irrelevant probe for the detection of pneumolysin was used as a control for sequence-specific binding. HE-stained and ISH slides were analyzed and images taken using a BX41 microscope (Olympus) with a DP80 Microscope Digital Camera and the cellSens™ Imaging Software, Version 1.18 (Olympus).

### **Virus titrations, RNA extractions and RT-qPCR**

To determine virus titers from 25 mg lung tissue, tissue homogenates were serially diluted and titrated on Vero E6 cells in 12-well-plates. Three days later, cells were formalin-fixed, stained with crystal

violet and plaques were counted. RNA was extracted from homogenized lungs, nasal washes and tracheal swabs using the innuPrep Virus DNA/RNA Kit (Analytik Jena) according to the manufacturer's instructions. We quantified RNA using a one-step RT qPCR reaction with the NEB Luna Universal Probe One-Step RT-qPCR kit (New England Biolabs) and previously published TaqMan primers and probes (SARS-CoV-2 E\_Sarbeco and hamster RPL18) (Corman et al., 2020; Zivcec et al., 2011) on a StepOnePlus RealTime PCR System (Thermo Fisher Scientific).

### **Statistical Analysis**

All statistical tests were performed using GraphPad Prism, version 8.4. For comparison of SHM number, ordinary one-way ANOVA tests with posthoc Tukey's multiple comparisons tests were used. Statistical significance of bodyweight changes from hamster experiments was tested using a mixed-effects model (two-way ANOVA) with posthoc Dunnett's multiple comparisons test in comparison to control group.

## SUPPLEMENTARY MATERIALS

### **Title: SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model**

Jakob Kreye<sup>†,\*</sup>, S Momsen Reincke<sup>†</sup>, Hans-Christian Kornau, Elisa Sánchez-Sendin, Victor Max Corman, Hejun Liu, Meng Yuan, Nicholas C. Wu, Xueyong Zhu, Chang-Chun D. Lee, Jakob Trimpert, Markus Höltje, Kristina Dietert, Laura Stöffler, Niels von Wardenburg, Scott van Hoof, Marie A Homeyer, Julius Hoffmann, Azza Abdelgawad, Achim D Gruber, Luca D Bertzbach, Daria Vladimirova, Lucie Y Li, Paula Charlotte Barthel, Karl Skriner, Andreas C Hocke, Stefan Hippenstiel, Martin Witzenrath, Norbert Suttorp, Florian Kurth, Christiana Franke, Matthias Endres, Dietmar Schmitz, Lara Maria Jeworowski, Anja Richter, Marie Luisa Schmidt, Tatjana Schwarz, Marcel Alexander Müller, Christian Drosten, Daniel Wendisch, Leif E Sander, Nikolaus Osterrieder, Ian A Wilson, Harald Prüss<sup>\*</sup>

<sup>†</sup> These authors contributed equally.

<sup>\*</sup> Correspondence to:


Jakob Kreye & Harald Prüss

German Center for Neurodegenerative Diseases (DZNE) Berlin

c/o Charité – Universitätsmedizin Berlin


CharitéCrossOver (CCO), Charitéplatz 1, 10117 Berlin, Germany

Email: [jakob.kreye@dzne.de](mailto:jakob.kreye@dzne.de); [harald.pruess@dzne.de](mailto:harald.pruess@dzne.de).




**Fig. S1 | SARS-CoV-2-S1 serum IgG response from COVID-19 patients.**

Serum IgG response determined as the normalized optical density (OD) in a SARS-CoV-2-S1 ELISA in relation to the time point of diagnosis defined by the first positive qPCR test. Upward arrowhead denotes the appearance of first symptoms. Downward arrowhead denotes the PBMC isolation. From patient CV01, PBMC samples were isolated at two time points as indicated by the second downward arrow with an asterisk (\*).



**Fig. S2 | Flow cytometry gating and characteristics of immunoglobulin sequences.**


(A-B) A representative flow cytometry plot from patient CV38 indicating gating on (A) CD19<sup>+</sup>CD27<sup>+</sup>antibody-secreting cells (ASC) and (B) SARS-CoV-2-S1-stained memory B cells (S1-MBC). Cells were pre-gated on live CD19<sup>+</sup> B cells. (C) Comparison of somatic hypermutation (SHM) count within immunoglobulin V genes combined from heavy and light chains of S1-reactive (S1+, blue) and non-S1-reactive (S1-, grey) mAbs. Statistical significance was determined using a one-way ANOVA ( $F = 19.22$ ) with posthoc Tukey's multiple comparisons tests. (ASC:  $n = 20$  S1+,  $n = 260$  S1-; S1-MBC:  $n = 102$  S1+,  $n = 50$  S1-). All expressed mAbs are displayed. Each triangle represents a S1+ (blue) or S1- (grey) mAb, isolated from an ASC (pointing downwards) or a S1-MBC (pointing upwards). (D-E) Length comparison of complementarity-determining region (CDR) 3 amino acid sequences between S1+ and S1- mAbs within (D) heavy and (E) light chains. Symbols and colors have the same meaning as in (C). (F) Frequency of RBD-binder (S1+RBD+) and non-RBD-binder (S1+RBD-) relative to all expressed mAbs (upper lanes) and relative to S1+ mAbs (lower lanes).



**Fig. S3. | Comparison of variable gene usage.**

Comparison of gene usage between SARS-CoV-2-S1-reactive (S1+) and non-reactive (S1-) mAbs is shown for immunoglobulin **(A)** variable heavy (IGHV), **(B)** variable kappa (IGKV) and **(C)** variable lambda (IGLV) genes. Bars depict percentage of gene usage of all expressed mAbs within each group.






**Fig. S4 | Clonal expansion and public clonotypes.**


(A) Pie charts represent clonal relationship of all expressed mAbs from each donor separately for antibody secreting cells (ASC) and S1-stained memory B cells (S1-MBC). mAbs were considered S1-reactive (S1+) or non-S1-reactive (S1-) based on SARS-CoV-2-S1 ELISA measurements. Antibodies were considered to be clonally expanded when they were isolated from multiple cells. (B) Circos plot displays all isolated mAbs from ten donors. Interconnecting lines indicate relationship between mAbs that share the same V and J gene on both Ig heavy and light chain. Such public or shared clonotypes in which more than 50% of mAbs are S1-reactive are represented as colored lines. Small black angles at the outer circle border indicate expanded clones within the respective donor. (C) Properties of public clonotypes from

S1+ mAbs according to the colors used in (B) with sequence similarities between mAbs isolated from different donors, also within complementarity-determining region (CDR) three. IGHV, IGHJ, IGKV, IGKJ, IGLV, IGLJ = V and J genes of immunoglobulin heavy, kappa, lambda chains; n.exp. = not expressed.




**Fig. S5 | Binding kinetic measurements of mAbs to RBD.**

Binding kinetics of mAbs to RBD were modeled (black) from multi-cycle surface plasmon resonance (SPR) measurements (blue, purple, orange). Fitted monovalent analyte model is shown. For CV07-200, neither a bivalent nor a monovalent analyte model described the data accurately (no model is shown). Three out of the 18 selected mAbs for detailed characterization (Top-18) were not analyzed using multi-cycle-kinetics: CV07-270 was excluded as it interacted with the anti-mouse IgG reference surface on initial qualitative measurements. CV07-255 and CV-X2-106 were not analyzed since they showed biphasic binding kinetics and relatively fast dissociation rates in initial qualitative measurements. Non-neutralizing CV03-191, a mAb not included in the Top-18 mAbs, was included in the multicycle experiments as it has the same clonotype as strongly neutralizing CV07-209 (Fig. S4C). All measurements are performed by using a serial 2-fold dilution of mAbs on reversibly immobilized SARS-CoV-2-S1 RBD-mFc.




**Fig. S6 | Competition of mAbs for RBD binding with ACE2 and between SARS-CoV-2 mAbs.**

(A) ELISA-based measurements of human ACE2 binding to SARS-CoV-2 RBD after pre-incubation with the indicated neutralizing mAbs. Values are shown relative to antibody-free condition as mean+SD from three independent measurements. (B) Competition for RBD binding between combinations of potent neutralizing mAbs is illustrated as a heat map. Shades of green indicate the degree of competition for RBD binding of detection mAb in presence of 100-fold excess of competing mAb relative to non-competition conditions. Green squares indicate no competition. Values are shown as mean of two independent experiments.




**Fig. S7 | Binding specificity of mAbs within coronaviruses.**

(A) Representative immunofluorescence staining on VeroB4 cells overexpressing spike protein of indicated coronavirus with SARS-CoV-2 mAb CV07-209 at 5  $\mu$ g/ml. For all other 17 of the selected 18 mAbs (Top-18, Supplementary Table ST4), similar results were obtained. (B) Binding of indicated mAbs to fusion proteins containing the RBD of indicated coronaviruses and the constant region of rabbit IgG revealed by ELISA. For all other Top-18 mAbs, similar results were obtained as for CV07-209. Values indicate mean+SD from two wells of one experiment.



**Fig. S8 | Representative staining on HEp-2 cells of selected S1-reactive antibodies.**

Representative HEp-2 cell staining with a commercial anti-nuclear antibody as positive control revealed nuclear binding (left). S1-reactive non-neutralizing mAb CV38-148 exhibited cytoplasmic binding (middle). Neutralizing mAb CV07-209 showed no binding (right). All mAbs selected for detailed characterization (Top-18, Supplementary Table ST4) revealed similar results like CV07-209 when used at 50  $\mu\text{g/ml}$ .



**Fig. S9 | Structural comparison of CV07-270/RBD and P2B-2F6/RBD complexes.**

(A) Structure of CV07-270 (pink) in complex with RBD (white). (B) Structure of P2B-2F6 (blue) in complex with RBD (white) (PDB 7BWJ) (Ju et al., 2020) (C) Structures of CV07-270/RBD and P2B-2F6/RBD were superimposed based on the RBD.

A

```

                                CDRH1                                CDRH2
CV07-250: QVQLVQSEAEVKEPGASVEVSCKASGYNFTNFAISWVRQAPGQGLEWMGWISGYNGDTNSAQKFL
IGHV1-18: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQ
                                31 32 33 34 35                                50 51 52 53 54 55 56 57 58 59 60 61 62 63 64


                                CDRH2                                CDRH3
CV07-250: GRVTMTTDTSTTTAYMELRSLRSDDTAVYYCAGSDNYGFPYNGMDVWGQGTVSS
IGHV1-18: GRVTMTTDTSTTSTAYMELRSLRSDDTAVYYCA-----
                                95 96 97 98 99 100 100A 100B 100C 100D 100E 101 102

                                CDRH1                                CDRH2
CV07-250: QSALTQPPSASGSPGQSVTISCTGTSSDLGAYHEVTWYQHYPGKAPKVMIYGVRKRPSGVPDRFS
IGHV2-8:  QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPDRFS
                                24 25 26 27 27A 27B 27C 28 29 30 31 32 33 34                                50 51 52 53 54 55 56

                                CDRH3
CV07-250: GSKSGNTASLTVSGLQDEDEADYYCSSYAGNDFVFGGGTKLTVL
IGHV2-8:  GSKSGNTASLTVSGLQAEDEADYYCSSYAGSNN-----
                                89 90 91 92 93 94 95 95A 96 97

```

B



C

```

                                CDRH1                                CDRH2
CV07-270: QVQLVESGGGLVKPGGSLRRLSCAASGFTFSDYYMTWIRQAPGKGLEWVSYISSSGSTIYYADSVKG
IGHV3-11: QVQLVESGGGLVKPGGSLRRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKG
                                31 32 33 34 35                                50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65

                                CDRH3
CV07-270: RFTISRDNAKNSLYLQMNSLRAEDTAVYYCARARGSSGWYRIGTRWGNWFDPWGQGTLTVSS
IGHV3-11: RFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR-----
                                95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 100G 100H 100I 100J 100K 101 102

                                CDRH1                                CDRH2
CV07-270: QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFS
IGHV2-14: QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFS
                                24 25 26 27 27A 27B 27C 28 29 30 31 32 33 34                                50 51 52 53 54 55 56

                                CDRH3
CV07-270: GSKSGNTASLTISGLQAEDEADYYCSSYTSSSNVFGGGTMLTVL
IGHV2-14: GSKSGNTASLTISGLQAEDEADYYCSSYTSS-----
                                89 90 91 92 93 94 95 95A 96 97

```

**Fig. S10 | Comparison of sequences of CV07-250 and CV07-270 to their putative germline sequences.**

- (A) Alignment of CV07-250 with the germline IGHV1-18 sequence (nucleotide SHM rate 5.8%) and IGLV2-8 (nucleotide SHM rate 5.4%).  
 (B) Somatic mutations V<sub>H</sub> S31H, V<sub>L</sub> G29A, V<sub>L</sub> N31H, V<sub>L</sub> Y32F, V<sub>L</sub> S34T, and V<sub>L</sub> L46V are located in the CV07-250 paratope with other



somatic mutations in all of the CDRs that may affect overall CDR conformation and interactions. Hydrogen bonds are represented by dashed lines. Distances between atoms are shown in solid lines. CV07-250 heavy chain is in dark cyan and light chain is in light cyan. SARS-CoV-2 RBD is in light grey. **(C)** Alignment of CV07-270 with the germline IGHV3-11 sequence (nucleotide SHM rate 0.7%) and IGLV2-14 (nucleotide SHM rate 0%). The regions that correspond to CDR H1, H2, H3, L1, L2, and L3 are indicated. Residues that differ from the germline are highlighted in red. Residues that interact with the RBD are highlighted in yellow. Residue positions in the CDRs are labeled according to the Kabat numbering scheme.

**Supplementary Table ST1 | Description of patient cohort.**

General	Patient ID (gender, age)	CV01 (m, 21)	CV03 (m, 46)	CV05 (m, 61)	CV07 (m, 32)	CV23 (f, 44)	CV24 (m, 64)	CV38 (m, 70)	CV48 (m, 48)	CV-X1 (m, 46)	CV-X2 (m, 57)
Patient history	Pre-existing conditions	N	CVD, Crohn's disease	N	N	atopic dermatitis, hypothyreosis	CVD	CVD	N	N	N
	Smoking	N	N	N	Y	N	N	Y (10 PY)	N	Y (7 PY)	N
Symptoms	Pulmonary and general symptoms	fever, cough, emesis	fever, cough, dyspnea, emesis	fever, cough, dyspnea, superinfection	fever, cough, dyspnea, respiratory failure	fever	fever, cough, dyspnea, emesis	fever, dyspnea, renal failure, atrial fibrillation	fever, cough, dyspnea, diarrhea	fever, cough, dyspnea, respiratory failure, diarrhea	fever, cough, epistaxis
	Neurological symptoms	loss of smell, muscle twitches	loss of smell, mood impairment, paresthesia	N	loss of smell	n/a	loss of smell	N	N	n/a	loss of smell
Disease course	Date symptom onset	17.02.2020	29.02.2020	27.02.2020	08.03.2020	20.03.2020	13.03.2020	12.03.2020	14.03.2020	15.03.2020	18.03.2020
	Days until diagnosis / hospitalization	13 / 13	10 / 11	3 / 13	5 / 6	0 / 0	7 / 8	6 / 14	10 / 9	11 / 12	2 / -
	SARS-CoV-2 serum IgG at PBMC isolation	2.0 / 3.8	6.4	5.7	6.6	1.2	n/a	8.9	6.4	n/a	n/a
	Days in hospital / on ICU	34 / 0	14 / 0	9 / 0	15 / 2	34 / 0	8 / 2	15 / 0	17 / 2	15 / 6	0 / 0
	Oxygen demand / days ventilation	N / 0	N / 0	N / 0	Y / 0	N / 0	Y / 0	Y / 0	Y / 0	Y / 3	N / 0
	Medication	N	N	AB, ACT	N	N	AB, ACT	AB, ACT, APT, Digitoxin	AB, ACT, APT, HCQ	AB, HCQ	N
Follow Up	Outcome	discharged	discharged	discharged	discharged	discharged	discharged	discharged	discharged	discharged	discharged

PBMCs from ten COVID-19 patients were included in immunoglobulin repertoire studies. General information, patients' history, symptoms of SARS-CoV-2 infection, disease course and outcome are listed for each donor. SARS-CoV-2 IgG is given as a ratio of optical density from time point of PBMC isolation ( $\pm$  one day).

Abbreviations: m = male, f = female, Y = yes, N = no, n/a = not available, CVD = cardiovascular disease, PY = pack years, AB = antibiotics, ACT = anticoagulation therapy, APT = antiplatelet therapy, HCQ = hydroxychloroquine.

**Supplementary Table ST2 | Immunoglobulin sequence and functional screening data of all isolated mAbs.**

mAb	Clonality	Source cell	Ig isotype	IGHV gene	IGHJ gene	CDR H3	SHM IGHV	IGKV/IGLV gene	IGKJ/IGLJ gene	CDR L3	SHM IGKV/IGLV	S1 reactivity (OD ratio)	RBD reactivity	Estimated IC <sub>50</sub> (ng/ml)
HL CV01-101		ASC	IgM	3-74	3	ARGSSNLFDI	7	1-44	3	AAWDDSLNGWV	4	0.1		
HL CV01-102		ASC	IgG1	3-21	4	ARSGGYSGYDYSHRIDY	25	2-14	3	SSYTLDDSTVV	12	n.exp.		
HK CV01-103		ASC	IgA1	1-69	4	ASGWGMEYSSSSADY	0	3-11	2	QQRSNWPPYT	1	0.09		
HL CV01-104	1-2	ASC	IgM	1-18	4	ARADETMVQGVIPNFDY	4	2-8	2	SSYAGSNNVV	3	0.1		
HK CV01-107		ASC	IgA2	3-74	6	ARGRDCGSSCYGYPYGMVDV	7	2-28	2	MQUALHTPYT	4	n.exp.		
HK CV01-109	1-3	ASC	IgG2	3-7	4	ARAGSVGVVDY	12	2-30	1	MQGTHWPWT	8	0.1		
HK CV01-110		ASC	IgA1	3-7	4	VRDRGYCVGDVICYTVLDY	27	1-6	4	LHDYNYPPPT	13	0.09		
HK CV01-111		ASC	IgM	3-15	1	TTWFYDIRDH	24	3-11	2	QQRSNWPPFT	11	0.09		
HL CV01-112	1-2	ASC	IgM	1-18	4	ARADDTMVQGVIPNFDY	14	2-8	3	SSYAGSNNVV	2	0.03		
HK CV01-113		ASC	IgM	3-15	4	ASIYYDF	13	1-17	2	LHYNVVPYT	18	n.exp.		
HL CV01-114		ASC	IgM	1-2	4	ARGDAVARTLNLDY	8	1-44	2	AAWDDSLNGV	3	0.09		
HK CV01-116	1-3	ASC	IgM	3-7	4	ARAGNIGAVDY	14	2-30	1	MQGTHWPWT	1	0.02		
HL CV01-117		ASC	IgA1	3-49	4	GLSYYYDNGGYYVPPIDV	20	2-8	3	SSYADSNLV	9	n.exp.		
HK CV01-118	1-1	ASC	IgM	3-9	3	AKNSPCADAVCYFDV	10	4-1	1	QQYYSAPRT	8	n.exp.		
HK CV01-120		ASC	IgA1	4-30-4	3	AREGLITIFGVARDAFDI	1	3-20	2	QQYGSSPRT	1	0.09		
HK CV01-121		ASC	IgA1	4-38-2	4	SIWGGVQGVLDY	22	3-15	2	QQYNDWPRT	7	0.09		
HK CV01-122	1-3	ASC	IgG2	3-7	4	ARAGSIASVDY	11	2-30	1	MQGTHWPWT	8	n.exp.		
HK CV01-123		ASC	IgM	3-7	4	AKGGWRYFDY	16	3-11	4	QQRSSWPLT	9	0.08		
HK CV01-124		ASC	IgM	3-23	4	AKYGSITIFGVIIIGYFYFDY	1	3-20	2	QQYGSSPAT	0	0.08		
HL CV01-125	1-2	ASC	IgA1	1-18	4	ARADYTMVQGVIPNFDY	7	2-8	2	SSYAGSNNVL	10	0.1		
HL CV01-126		ASC	IgA2	5-51	6	AGHVRYCISTNCYHYGMDV	5	5-45	3	MIWHTSAWV	6	0.10		
HK CV01-128	1-3	ASC	IgG2	3-7	4	ARAGDRGAVDY	13	2-30	1	MQGTHWPWT	8	0.11		
HL CV01-129	1-2	ASC	IgA1	1-18	4	ARADYTMVQGVIPNFDY	0	2-8	2	SSYAGSNNVV	4	n.exp.		
HK CV01-130		ASC	IgM	3-7	3	ARPGYSGNNWGEAFDI	0	4-1	1	QQYYDTLWT	13	0.09		
HK CV01-132		ASC	IgG1	4-59	6	ARDRGYNWNYYYYYGMDV	0	3-20	1	QQYGSSPST	2	0.1		
HK CV01-133	1-3	ASC	IgG2	3-7	4	ARAGSRGSVDY	21	2-30	1	MQGTHWPWT	13	0.1		
HK CV01-134		ASC	IgM	3-30	6	AKEKLDCSSTSCYFGFIYYYYMDV	0	1-12	2	QQANSFPLT	1	0.09		
HL CV01-135		ASC	IgG1	3-11	4	ARESYEGSSFDY	10	6-57	3	QSYDSSNRRV	3	0.1		
HK CV01-137		ASC	IgG2	3-7	4	ARDYGRCGDY	18	3-11	2	QQGGNWPRPT	9	0.11		
HK CV01-138		ASC	IgA1	4-39	5	ARHGYYITIFGVIIIPGWFDP	0	3-15	1	QQYNNWPPWT	2	0.07		
HL CV01-139		ASC	IgM	4-39	4	ARHPDNELLPFDY	0	3-21	1	QVWDDSSSDSYV	2	0.11		
HK CV01-140		ASC	IgM	3-30-3	2	ARDPRNYCHSNTCPVWYFDL	17	3-20	2	QQYGSSPRT	6	0.08		
HL CV01-141		ASC	IgG1	3-33	4	AREGNYGDYGGSFYD	0	3-10	3	YSTDSSGNHRV	0	n.exp.		
HL CV01-142		ASC	IgM	4-30-4	2	ARGPRITIFGVVIYWFYDL	0	1-40	2	QSYDSSLGSGV	1	0.09		
HL CV01-144		ASC	IgG1	3-30	4	ARRDRIFEFGATREALDF	22	1-40	1	QSYDSSLGYSV	15	0.08		
HK CV01-145		ASC	IgM	3-23	5	AKVTWTTTGDS	19	1-5	1	QQYNSYPWT	7	0.10		
HK CV01-146	1-3	ASC	IgG1	3-7	4	ARAGDRGAVDY	17	2-30	1	MQGTQWPWT	10	0.09		
HK CV01-147		ASC	IgG1	3-30-3	5	ARERVNGRWLQLLTP	20	1-5	4	QQYDAYLS	16	0.09		
HK CV01-148	1-3	ASC	IgM	3-7	4	ARAGDRGAVDY	10	2-30	1	MQGTHWPWT	2	0.08		
HK CV01-149		ASC	IgM	1-18	4	AGYPRYNWYDNRYYFDF	7	1-39	5	QQSYSAPIT	9	n.exp.		
HL CV01-151	1-2	ASC	IgM	1-18	4	ARADDTMVQGVIPNFDY	2	2-8	2	SSYAGSNNVV	4	0.07		
HK CV01-152		ASC	IgA1	1-3	6	ARGVGATIPYYYYYMDV	2	1-5	1	QQYNSYSWT	1	0.1		
HK CV01-153		ASC	IgG1	4-4	6	AKVGGGNADHGPYYYYYMDV	37	1-9	2	QELNRYPRPT	17	0.07		
HK CV01-154	1-1	ASC	IgM	3-9	3	AKNSASCADDLCYFDI	15	4-1	1	QQYYSGPRT	7	0.08		
HK CV01-155		ASC	IgM	3-11	4	ARALPGGITIFGVVITEYFYD	0	3-20	2	QQYGSSSYT	2	0.08		
HL CV01-158		ASC	IgG2	3-21	3	ARGDDYGEYTGAFDA	2	3-1	2	QAWDSSTVV	3	0.09		
HK CV01-159		ASC	IgA1	1-46	4	ARGGETQQLRVWDQKTDD	23	1-17	4	LQYNSYPLT	12	0.11		

mAb	Clonality	Source cell	Ig isotype	IGHV gene	IGHJ gene	CDR H3	SHM IGHV	IGKV/IGLV gene	IGKJ/IGLJ gene	CDR L3	SHM IGKV/IGLV	S1 reactivity (OD ratio)	RBD reactivity	Estimated IC <sub>50</sub> (ng/ml)
HK CV01-163	1-3	ASC	IgA1	3-7	4	ARAGSVGTVDY	22	2-30	1	MQGTHWPWT	16	0.08		
HK CV01-166		ASC	IgA1	3-15	4	TTEKGRYHLGGVFAN	11	4-1	4	QQYYSTPLT	8	n.exp.		
HL CV01-168		ASC	IgA1	5-51	4	VWTSRGYFDH	6	7-43	3	LFYYGGAWV	9	n.exp.		
HL CV01-169		ASC	IgM	3-30	4	ARDLSSGWSLDS	3	2-14	3	SSYTSSNTWV	4	0.07		
HL CV01-170		ASC	IgM	4-4	6	ARYCSSTSCYGYYYGMDV	0	2-8	1	SSYAGSISYV	2	0.08		
HK CV01-171		ASC	IgG1	4-4	3	AKGGGSGWYYDAFDI	17	3-15	1	QQYNNWLR	12	0.11		
HL CV01-174		ASC	IgM	1-18	4	ARDWNYARGNFDY	3	2-14	2	SSYTSSSSV	1	0.14		
HK CV01-175	1-3	ASC	IgM	3-7	4	ARAGGVGTVDY	11	2-30	1	MQGLWPWT	2	0.1		
HL CV01-176	1-2	ASC	IgA1	1-18	4	ARADHTMVQGVIPNFDY	3	2-8	2	SSYTGRKNV	6	0.1		
HK CV01-180	1-3	ASC	IgM	3-7	4	ARCDMAGTTDY	5	2-30	1	MQGLWPWT	2	0.1		
HK CV01-181		ASC	IgG1	3-21	2	ARDLEGVETIFGVVPIPAYWYFDL	0	2-28	4	MQUALQRTL	3	0.08		
HL CV01-182		ASC	IgG1	3-23	4	AKDLKIGTLGWYYDFWSGYLPDPSNKIFDY	0	1-40	3	QSYDSSLGWW	0	0.1		
HL CV01-183		ASC	IgM	3-73	3	TRVNIQGFYDALDI	6	1-51	2	GTWSSLSVV	7	0.11		
HK CV01-184		ASC	IgG2	4-59	4	ARFSSAAGVWALDH	11	4-1	2	QQYTTPTFT	7	n.exp.		
HL CV01-185		ASC	IgA1	1-69	6	ACDMVQGVAVLDV	13	2-14	2	SSYTSSSTV	9	0.13		
HK CV01-186		ASC	IgG2	4-59	5	ARHGKSIPYSNYDWFDP	0	1-39	3	QSYSTLPFT	0	0.09		
HK CV01-188		ASC	IgM	3-72	4	ARDLGANGDRFGN	4	4-1	1	QQYYSTPLT	2	0.08		
HK CV01-193		ASC	IgA1	3-15	4	ATDLGDYGYDMRS	13	1-12	2	QQANSFPYT	7	0.11		
HL CV01-194		ASC	IgM	4-59	4	AKKADPHSAFDY	6	2-11	1	CSYAGSYTYV	6	0.09		
HL CV01-195		ASC	IgM	3-7	1	VRELVVGRAEYFQD	0	1-44	2	AAWDDSLNGRV	1	3.37	++	>250
HK CV01-196		ASC	IgG1	3-30	3	AKDPGMLYPSAFDM	14	3-15	4	QQYNNWPPLT	13	n.exp.		
HL CV01-197		ASC	IgM	3-23	4	AKDQDGHYGGNPDMDH	10	2-8	3	SSYAGSNKMV	11	n.exp.		
HL CV01-198		ASC	IgG2	3-15	4	ATLTYGYSY	11	2-14	1	SSYTSSSTTYV	63	n.exp.		
HK CV01-199		ASC	IgA1	3-74	4	ASNFNRRNDGY	14	2-30	4	IQSTHWPPN	13	n.exp.		
HK CV01-202		ASC	IgG1	4-30-4	4	ARMGNMFGYSVVDV	22	1-39	2	LQYSAPYT	20	n.exp.		
HL CV01-203		ASC	IgA2	3-30	6	AKSEGFYFYGVVDV	9	1-47	1	AACDDSLSGHV	3	n.exp.		
HK CV01-205		ASC	IgG1	5-51	5	AREARWSFSPWFDP	6	3-15	2	QQYNNWPRF	7	n.exp.		
HK CV01-211		ASC	IgA1	5-51	4	ARLSSGWYGGFNFDY	0	3-20	2	QQYGSSPVYT	0	n.exp.		
HL CV01-212		ASC	IgM	3-30	4	AKCSYTSICKGWDAHA	14	2-14	2	SSFTTSYTLV	11	n.exp.		
HK CV01-213		ASC	IgG1	3-64	4	ARLQGTGYLDY	12	3-20	2	HQYSSSPRT	9	n.exp.		
HL CV01-215		ASC	IgM	3-48	5	ARQWAVNWVFP	7	2-14	2	SSHTSSSTV	8	n.exp.		
HK CV01-220		ASC	IgA1	3-48	6	ARDVGYTESTSTGMDV	7	3-11	5	QQRGNWPPAT	11	n.exp.		
HL CV01-221		ASC	IgA1	3-30-3	4	ARGAPVDY	6	2-8	7	N/A	9	n.exp.		
HL CV01-222		ASC	IgA1	3-23	4	AKPGGEWYSSGWRFDY	2	1-47	2	AAWDDSLSGPV	0	n.exp.		
HL CV01-223		ASC	IgM	3-23	3	AKCGRTSCRVDAFDI	27	8-61	3	VLSMGGGVV	13	n.exp.		
HL CV01-225		ASC	IgA1	3-53	3	ARDGGGSYPHRAFDI	1	2-14	2	SSYTSSSTSDV	2	n.exp.		
HL CV01-226		ASC	IgG1	4-39	6	ARHATGTPPYYYYMDV	2	3-1	1	QAWDSSTACV	3	n.exp.		
HL CV01-227		ASC	IgA1	3-30	4	AKGSPLLFGGVVDY	0	5-39	3	AIWYSSSLV	1	n.exp.		
HK CV01-228		ASC	IgA1	3-7	4	ARVGASDYDYVWGTRTLDS	11	4-1	1	QQCLTTPPWT	12	n.exp.		
HK CV01-229		ASC	IgG2	5-51	4	ARPYGAGTAHYFDY	9	4-1	4	QQYGTPTHT	8	n.exp.		
HL CV01-231	1-4	ASC	IgA1	4-39	6	ARHFHPGNYYYYYMDV	6	3-1	2	QAWDSSTYVV	3	n.exp.		
HL CV01-232		ASC	IgM	4-39	4	ARKYGLDHFY	1	8-61	3	VLYMGSGISV	3	n.exp.		
HL CV01-233		ASC	IgM	4-39	3	ARSDARFLEWLFDPDAFDI	3	2-23	2	CSYAGSTTFV	3	n.exp.		
HL CV01-234		ASC	IgM	3-30	5	ARGSPFGGIRSGLGP	20	1-27	1	QKYNAPWT	11	n.exp.		
HL CV01-238	1-4	ASC	IgG1	4-39	6	ARHPTGSGSYQYYYYIDV	3	3-1	2	QAWDSSTV	2	n.exp.		
HL CV01-241		ASC	IgA1	3-66	3	ARDRGYDSSGYTAADAFDI	2	1-5	1	QQYNSYST	6	n.exp.		
HL CV01-242		ASC	IgG1	4-31	5	ARGGYRNWFDP	3	2-11	3	CSYAGSYTWV	2	n.exp.		
HK CV01-244		S1-MBC	IgG1	5-10-1	6	ARLKGSPVPPYYNYMDV	18	2-28	4	MQLQTPFI	7	n.exp.		
HK CV01-249		S1-MBC	IgA1	3-30-3	3	ARHNRAGQPSFDV	21	1-39	5	QTYSVPTT	32	0.08		
HK CV01-254		S1-MBC	IgM	3-7	4	ASLLGGTVVNDY	4	4-1	2	QQYYSTQYT	2	0.09		

mAb	Clonality	Source cell	Ig isotype	IGHV gene	IGHJ gene	CDR H3	SHM IGHV	IGKV/IGLV gene	IGKJ/IGLJ gene	CDR L3	SHM IGKV/IGLV	S1 reactivity (OD ratio)	RBD reactivity	Estimated IC <sub>50</sub> (ng/ml)
HK CV01-257	S1-MBC	IgM	3-48	6	ARHPWDDYGDYYYYYMDV	5	3-20	2	QQYGSSLNT	2	10.92	++	>250	
HL CV01-258	S1-MBC	IgG1	4-59	6	ARAVHGVDTGMVYYYYHYMDV	7	3-21	2	QVWDNSIDHVV	5	0.08			
HL CV01-260	S1-MBC	IgA2	1-8	4	ARGREYDFWGSYYN	3	2-14	3	SSYTRSNTVV	6	0.14			
HK CV01-266	S1-MBC	IgA1	3-15	3	TSERWLDAFDI	28	1-39	5	QQSYRSPIT	24	n.exp.			
HL CV01-273	S1-MBC	IgA1	4-4	4	ARGWKGPPGLY	2	2-23	3	YSYAGSSTWV	4	7.10	-	>250	
HK CV01-274	S1-MBC	IgM	3-30	4	AKDNGDYACFDY	0	4-1	4	QQYYSTPLT	0	0.07			
HL CV01-276	S1-MBC	IgA1	1-2	6	ARDPFEEYDFWGSYYRGGMDV	2	2-14	3	SSYSSSTRV	1	n.exp.			
HK CV03-101	ASC	IgG1	1-2	4	ARGLITWYYYDSSAVDY	0	3-20	1	QQYGSSPWT	0	0.1			
HK CV03-103	ASC	IgM	3-21	5	ARDPDGHRSGWFDWFDP	3	1D-12	5	QQANSFPIT	4	n.exp.			
HL CV03-104	ASC	IgG1	1-18	6	ARDSHYDSSGYYLYYYYGTDV	1	3-25	1	QSADSSGTYV	0	0.09			
HK CV03-106	3-2	ASC	IgG1	4-31	3	ARGRTIFGVVSGAFDI	0	3-20	4	QQYGSSPLT	1	0.02		
HK CV03-107	3-2	ASC	IgG1	4-31	3	ARGRTIFGVVSGAFDI	0	3-20	4	QQYGSSPLT	2	0.10		
HL CV03-108	ASC	IgG1	3-15	6	TKTKNPPAYDFWGSYYRGRPPYKYGMDV	20	1-40	1	QSYDNLSEYDDV	10	0.1			
HL CV03-109	ASC	IgG1	5-10-1	4	ARHVGVGATHSPFDY	0	1-40	2	QSYDSSLGPTV	0	0.12			
HK CV03-110	ASC	IgG1	3-48	4	ARDLGSWYLLDFDY	1	1-5	1	QQYNSYPRT	0	0.08			
HK CV03-112	ASC	IgG1	3-48	5	GRSSSWRYNWFDP	20	3-15	1	QQYNNWPPWT	13	0.03			
HL CV03-113	ASC	IgG1	3-15	4	TTDPYIEISSGYSPDY	44	2-11	2	N/A	34	0.09			
HL CV03-116	ASC	IgA1	4-59	6	ARVQGRGSGSYSAYYYGMDV	0	1-40	1	QSYDSSLGTV	1	0.1			
HL CV03-117	3-3	ASC	IgG1	1-46	6	LRDGISTFGVNNHYAMDV	16	2-14	1	SSYSSSTVV	11	n.exp.		
HL CV03-118	3-3	ASC	IgG1	1-46	6	ARDGISTFGVVKHYAMDV	26	2-14	1	SSYTTTTLV	26	n.exp.		
HL CV03-120	ASC	IgG1	3-21	6	ARDSLITIFGVVIEAPDDYGMV	0	2-14	2	SSYSSSTVV	2	n.exp.			
HL CV03-121	3-1	ASC	IgG1	3-23	4	AKDYFVPPAALYDY	0	1-51	2	GTWSSLSAGV	3	n.exp.		
HL CV03-123	ASC	IgG1	3-23	5	VKELDQLTLGGWFDV	36	2-23	3	CSYVGTATVV	26	0.11			
HL CV03-124	ASC	IgG1	5-51	4	ASSVRYDFWDFDY	0	1-44	1	AAWDDSLNGYV	0	n.exp.			
HK CV03-129	ASC	IgG1	1-69	4	ARARRPTYSSSWGTFDY	0	1-39	1	QQSYSTPWT	0	0.09			
HK CV03-130	ASC	IgG1	4-59	4	ASGTYGPPYLFDY	19	1-5	1	QKYNTYPGT	12	n.exp.			
HK CV03-131	ASC	IgM	3-11	4	ARAGDMIVAAFDY	0	3-20	4	QQYGSSPLT	0	0.08			
HK CV03-132	ASC	IgG1	3-7	6	ARGPQMVAALFPYYYYGMDV	0	1-27	1	QKYNSAPWT	0	0.1			
HK CV03-135	ASC	IgG1	3-64	3	VMELYGSDVFDL	22	1-39	1	QQSYRSTWT	18	0.1			
HL CV03-138	ASC	IgM	3-74	4	ASYTWGRI	1	2-14	2	SSYTRSTLVV	2	0.08			
HK CV03-139	ASC	IgM	4-39	6	ASQGPLPILYDILTYGLDYGGYGMV	2	2-28	4	MALQTLPLT	1	0.09			
HK CV03-140	ASC	IgG1	3-49	4	TRDAYYVSGSYSEGGH	0	3-11	3	QQRSNWPLFT	0	0.09			
HK CV03-141	ASC	IgG1	4-38-2	6	ARDVTGYDNEYYYYGLDV	24	4-1	1	QQYYSSPRT	9	0.08			
HL CV03-142	ASC	IgM	3-53	4	AREGPDSGYLDY	7	4-69	3	QWGTGIRV	6	0.11			
HK CV03-143	ASC	IgG1	3-48	4	ARDSGFWSGYYPGNFNY	0	1-33	4	QQYDNLPLT	1	6.43	++	>250	
HK CV03-144	ASC	IgG1	1-18	6	ARDPWIELRPPRNYNGMDV	11	2-28	1	MALQTPRT	4	0.08			
HL CV03-145	ASC	IgG1	1-46	4	ARDSSDCSGGSCYRFDY	0	1-44	1	AAWDDSLNGYV	0	n.exp.			
HK CV03-146	ASC	IgM	3-23	4	AKDRTVTKGLFLYDDC	10	1-39	5	QQSYSTPIT	6	0.08			
HL CV03-147	3-4	ASC	IgA1	3-23	4	ASQTGTGEVDY	0	3-1	1	QAWSSSTGV	0	4.2	-	n.t.
HL CV03-148	3-1	ASC	IgG1	3-23	4	AKGPRLLWFGELSPFDY	1	1-51	2	GTWSSLSALV	1	4.58	-	n.t.
HL CV03-150	3-5	ASC	IgA1	3-23	6	VKSGSDIERMVSTLRYFYGLEV	22	1-47	3	AVWDDSLSAWV	12	n.exp.		
HL CV03-151	3-5	ASC	IgA1	3-23	6	VKSGSDIERMVSTLRYFYGLDV	17	1-47	3	AVWDDSLSAWV	10	n.exp.		
HL CV03-152	ASC	IgG1	3-30	4	AKSGEVFWFRFRDYLDY	11	1-44	2	AAWDDRLNGVV	12	0.1			
HK CV03-153	ASC	IgM	3-74	4	ARDSTSTSCYESMK	7	1-5	1	QHYNSYPWM	5	0.12			
HK CV03-154	ASC	IgG1	1-24	6	ATSTVIAAGTVHYYYYGMDV	0	2-24	2	MQATQFPYT	0	0.11			
HK CV03-155	ASC	IgG1	3-33	6	ARDEKAYDFWSGYLSYYYGMDV	1	2-30	2	MQGTHWPPYT	0	0.09			
HK CV03-156	ASC	IgG1	5-10-1	4	ARLLYYYDSSGYLLPSPIDY	0	1-33	4	QQYDNLTLT	0	0.54	++	>250	
HL CV03-158	3-5	ASC	IgA1	3-23	6	VKSGSDIERMVSTLRYFYGLDV	16	1-47	3	AVWDDSLSAWV	10	0.1		
HL CV03-160	ASC	IgM	5-10-1	4	ARLGADSSGYLLPSPGIGY	1	1-40	3	QSYDSSLGSKV	0	0.09			
HL CV03-161	ASC	IgG1	4-39	2	ARQRKGWLQLRGNWYFDL	2	3-10	2	YSTDSSGNQVV	0	0.09			

mAb	Clonality	Source cell	Ig isotype	IGHV gene	IGHJ gene	CDR H3	SHM IGHV	IGKV/IGLV gene	IGKJ/IGLJ gene	CDR L3	SHM IGKV/IGLV	S1 reactivity (OD ratio)	RBD reactivity	Estimated IC <sub>50</sub> (ng/ml)
HL CV03-162		ASC	IgM	3-74	4	ARGGGTVVTPGPDY	11	4-69	2	QTWGIGTHDVI	6	0.07		
HL CV03-163	3-5	ASC	IgG1	3-23	6	VKGSGLDIERMVDALRYFYGMDV	27	1-47	3	AAWDDSLSAWV	15	1.17	-	n.t.
HK CV03-166		ASC	IgA1	4-4	5	TRLYCSSGACYLGP	26	3-20	1	QQYGRSPT	12	0.08		
HL CV03-167		ASC	IgG1	1-46	5	ARGRDWFDP	1	2-23	3	CSYAGSSTWV	5	0.11		
HK CV03-168		ASC	IgG1	1-69	6	AREAFYDILTGSSTPNHYYYGMDV	0	2-28	1	MQALQTPWT	0	0.1		
HK CV03-169		ASC	IgG1	3-74	4	ARDFYYDSSGFYD	0	1-39	1	QQSYSTPPWT	0	7.53	-	n.t.
HL CV03-170		ASC	IgG3	4-4	3	ARDTIGGHAFDI	0	3-21	3	QVWDDSSDHRV	2	0.09		
HL CV03-172		ASC	IgG1	1-24	5	ATSTLFSSVVPASWFDP	0	2-14	2	SSYTSSTPVV	0	0.09		
HK CV03-173		ASC	IgM	1-2	3	ARILPSDYFWSGYYSIQETDAFDI	0	1-5	2	QQYNSYSS	0	0.08		
HK CV03-174		ASC	IgG1	5-51	4	ARQVFIAVAGTGFYD	1	2-28	1	MQALQTPWT	0	2.68	-	> 250
HL CV03-175		ASC	IgG1	4-31	5	ARDFVSGPLMTENVPIYDSSGYLTRYNWFD	0	1-51	2	GTWDDSSLSAVV	3	0.1		
HL CV03-177	3-4	ASC	IgG1	3-23	4	AKDSGSYLLN	0	3-1	1	QAWDSSTYV	1	3.3	-	n.t.
HL CV03-179		ASC	IgG1	1-2	6	AREDGSSPLGGMDV	0	3-1	1	QAWDSSTYV	1	0.09		
HL CV03-180	3-5	ASC	IgA1	3-23	6	VKGSGLDIERMVSSLRYFYGLDV	15	1-47	3	AVWDDSLSAWV	12	0.09		
HK CV03-181		ASC	IgG1	1-69	4	ASTGHHQDASDY	0	3-11	3	QQRSNWPPRVT	0	0.07		
HL CV03-182		ASC	IgG1	1-2	4	ARERLAAAGTDFDY	1	1-40	1	QSYDSSLSDYV	2	0.09		
HL CV03-183	3-5	ASC	IgA1	3-23	6	VKGSGLDIERMVSSLRYFYGLDV	15	1-47	3	AVWDDSLSAWV	10	0.13		
HL CV03-185		ASC	IgG1	4-4	6	ARRGHTLLWYYYGMDV	0	1-51	7	GTWDDSSLSAGAV	2	1.82	-	> 250
HL CV03-186		ASC	IgG1	3-48	6	ARGRQLPFYYYYGMDV	0	1-40	1	QSYDSSLSGSV	0	0.12		
HL CV03-188	3-5	ASC	IgA1	3-23	6	VKGSGLDIERMVSTLRYFYGLDV	16	1-47	3	AVWDDSLSAWV	14	0.08		
HK CV03-190		ASC	IgG1	4-4	6	ARGMGYDFWSGSYSSYYGMDV	0	1-16	4	QQYNSYPLT	0	0.35	-	> 250
HK CV03-191		ASC	IgM	3-11	4	ARDLGYNRRFDY	0	1-33	4	QQYDNLPLT	1	6.16	++	> 250
HK CV03-192		ASC	IgG1	3-15	6	TTDPLRYDSSGYLYGMDV	1	2-28	4	MQALLTPST	1	0.12		
HL CV03-193		ASC	IgM	3-53	3	ARGGSWPNVFDI	11	8-61	3	VLYMGSGI WV	8	0.1		
HL CV03-195		ASC	IgG1	1-18	6	ARDRLRVRGVIKYYYYGMDV	0	3-25	3	QSADSSGTHWV	2	0.17		
HK CV05-101		ASC	IgA1	3-30	4	AKDRGYSSSWFSLDS	13	3-20	4	QQYGSRLRT	9	n.exp.		
HK CV05-102	5-1	ASC	IgM	1-3	3	AREDTFSVFGVTRGNAYDV	26	3-20	1	QQYGVSPRT	18	n.exp.		
HK CV05-104		ASC	IgA1	5-51	4	ARLGRSLQPNLGF DL	28	2-30	4	MQGSHWPLT	23	0.14		
HK CV05-107		ASC	IgG1	3-21	4	ARDSESAWNRIGNFYFDL	34	3-15	5	QQYNDWLIT	19	0.07		
HK CV05-108		ASC	IgG1	5-10-1	6	ARHHLKRGYATRYGMDV	0	1-39	1	QQSYSTPWT	0	0.12		
HK CV05-109		ASC	IgA1	4-31	4	ASLEGPYCSDDTTCYEGGQGLDY	11	3-11	1	HQRGNWWT	6	0.09		
HK CV05-110	5-1	ASC	IgG1	1-3	3	AREDTFSVFGVTRGNAYDV	26	3-20	1	QQYGVSPRT	18	0.08		
HL CV05-111		ASC	IgA1	3-33	6	ARDLDGDYVTTYGMDV	1	2-14	2	SSYTSSTPVV	1	8.39	++	> 250
HK CV05-113		ASC	IgG1	3-30	2	ASGDGYRNFWYFDI	31	2-28	4	MQALQTPPT	13	0.09		
HL CV05-114		ASC	IgG1	3-30-3	4	ARTVGDYGDY	0	3-1	2	QAWDSSTVV	0	0.27		
HK CV05-115		ASC	IgG1	3-48	6	ARDRGGYSGYGPYYGMDV	0	1-39	1	QQSYSTPWT	0	5.17	-	n.t.
HL CV05-116		ASC	IgA1	4-38-2	1	N/A	58	2-23	3	CSYAGAGSSNVV	18	n.exp.		
HK CV05-117		ASC	IgM	3-23	6	AKEKTSWLVAYYYGLDV	31	1-9	2	QQVNSHPHT	13	0.11		
HK CV05-118	5-2	ASC	IgA1	4-31	3	ARDYPFCGADCPWVDVFDI	23	3-15	1	QQYSNWPRT	30	0.09		
HK CV05-119		ASC	IgG1	3-30	4	AKPVGSSGYEYGGKPIDY	0	1-5	1	QQYNSYWT	3	0.12		
HL CV05-119		ASC	IgG1	3-30	4	AKPVGSSGYEYGGKPIDY	0	3-21	3	QVWDDSSDHWV	2	0.1		
HL CV05-120		ASC	IgG1	5-51	4	ARNRAGVIDY	0	6-57	3	QSYDSSNLWV	1	0.09		
HL CV05-121		ASC	IgA1	1-8	3	VRERIDYDHSGVSTSAFEF	27	1-44	1	GGWDDSLNGYV	17	0.09		
HL CV05-122		ASC	IgG1	3-23	6	AKGGYCSGGNCKMAHSYYGLDV	21	1-47	3	AAWDDSLSGHWV	7	0.07		
HK CV05-125		ASC	IgM	4-39	5	ASSNTASTMIVVVQRNWFDP	0	3-15	5	QQYNNWPIT	1	0.1		
HK CV05-126		ASC	IgG1	3-48	4	ARDRARAKWLAYSNYFDY	0	3-15	5	QQYNNWPL	0	0.11		
HL CV05-127		ASC	IgG1	3-33	4	ARDRVSSWEYFDY	0	3-10	2	YSTDSSGNHRGV	1	0.12		
HL CV05-129	5-3	ASC	IgG1	4-59	6	ARDRVSGGMDV	0	3-21	2	QVWDDSSDHWV	2	n.exp.		
HL CV05-131		ASC	IgA2	3-23	4	ARGYIGYCSGSTCTTNGGGDY	23	1-51	2	VTWDDSSLSAGV	8	n.exp.		
HL CV05-134		ASC	IgA1	3-23	3	AKAGIRGGISMVRAHFDI	6	2-8	1	SSYAGSNNFV	1	0.08		

mAb	Clonality	Source cell	Ig isotype	IGHV gene	IGHJ gene	CDR H3	SHM IGHV	IGKV/IGLV gene	IGKJ/IGLJ gene	CDR L3	SHM IGKV/IGLV	S1 reactivity (OD ratio)	RBD reactivity	Estimated IC <sub>50</sub> (ng/ml)
HK CV05-135		ASC	IgG1	3-33	4	AREDTAMVQRFDY	0	1-39	2	QQSYSTHT	0	0.11		
HL CV05-135		ASC	IgG1	3-33	4	AREDTAMVQRFDY	0	3-1	2	QAWDSSNVV	2	0.1		
HK CV05-136		ASC	IgG1	1-69	6	ARGRDIVVESTDQDPMDV	14	4-1	5	QQYYSTSSIT	6	0.07		
HK CV05-138	5-2	ASC	IgA1	4-31	3	ARDYPCFGADCPWVDVFDI	15	3-15	1	QQYNNWPRT	12	0.06		
HL CV05-139		ASC	IgG3	3-23	6	AKDFSGANGDYYYGMDV	0	3-25	3	QSADSSGTWV	2	0.09		
HK CV05-140		ASC	IgG1	4-59	4	AAGGGSGFYF	30	1-5	2	QQYKSSST	19	0.09		
HL CV05-143		ASC	IgG1	4-59	4	ARDRVAAGVDY	1	3-21	2	QVWDSDDHVV	2	0.09		
HL CV05-144		ASC	IgG1	3-30-3	6	ARTPGDGMV	0	3-10	2	N/A	1	0.1		
HL CV05-145		ASC	IgG1	5-10-1	4	ARHAIYCSGGSCYAFDY	1	1-41	2	N/A	3	n.exp.		
HK CV05-146	5-2	ASC	IgA1	4-31	3	ARDYPCFGADCPWVDVFDI	22	3-15	1	QQYNNWPRT	24	0.09		
HK CV05-148		ASC	IgG1	4-39	4	ARQRTHIFGVVHFYDY	1	4-1	1	QQYYSTPWT	1	0.1		
HK CV05-149		ASC	IgA1	4-59	6	ARGWGFPGSTNVHFYFGLDV	29	1-9	1	QLNSYRT	16	0.1		
HL CV05-151		ASC	IgM	4-59	6	AAGEVVTAISSYYGMDV	0	3-1	2	QAWDSSSVV	2	0.4	-	>250
HK CV05-152		ASC	IgM	3-15	4	TTERIYDYVWGSYRYSY	1	3-20	3	QQYGSSPVT	1	0.09		
HK CV05-153		ASC	IgA1	4-4	4	ARDLNV	28	3-15	3	QQYVNWPF	26	0.07		
HK CV05-155		ASC	IgM	1-2	6	ARALRITMIVVTHYGMDV	0	3-20	2	QQYGSSPYT	0	0.1		
HK CV05-157		ASC	IgG1	3-48	4	ARDKDFWGSNFDY	15	1-33	2	QQYDNLV	7	0.1		
HL CV05-159		ASC	IgG1	4-38-2	4	ARDKVDYPPYFDY	1	3-21	2	QVWDSDDHRV	2	0.08		
HK CV05-162		ASC	IgG2	3-21	4	ARDQWSGTTVTSMGH	15	1-5	2	QQYDSNWYT	15	0.09		
HK CV05-163		ASC	IgG1	1-2	6	AREVMVRGALPPYGMV	0	3-11	4	QQRSNWPPVT	0	10.44	++	25-250
HK CV05-164	5-2	ASC	IgA1	4-31	3	ARDYPCFGADCSWVDVFDI	21	3-15	1	QQYNNWPRT	13	0.1		
HK CV05-165		ASC	IgA1	3-74	4	AREGGDGFY	13	1-5	4	QQYQSYPLA	14	0.1		
HK CV05-167		ASC	IgG1	1-69	3	ARGVEMATILPDDAFDI	0	3-15	4	QQYNNWPPVT	0	0.09		
HL CV05-169		ASC	IgA1	1-69	4	ARGSTHNNLFVMDY	22	7-46	2	FLSYSGVRGLFVV	17	0.06		
HL CV05-170		ASC	IgG1	1-2	6	ARVDTTGTTFWLYYYGMDV	0	3-1	2	QAWDSSTALVV	1	0.11		
HK CV05-171		ASC	IgG1	4-30-4	4	ARLHGDYFFDY	0	1-39	2	QQSYSTHT	5	n.exp.		
HL CV05-171		ASC	IgG1	4-30-4	4	ARLHGDYFFDY	0	3-1	2	QAWDSSV	0	0.09		
HK CV05-172		ASC	IgM	4-30-4	5	ARLSMTTVTRGNWFDP	0	1-39	2	QQSYSTHT	0	0.08		
HL CV05-174		ASC	IgG1	1-2	4	ARDLSNGSSFDY	0	3-1	2	QAWDSSTADV	0	0.11		
HK CV05-175		ASC	IgG1	1-46	3	VQDLGVRGRRALDV	22	2-28	2	FQALQTPYT	7	0.11		
HK CV05-176		ASC	IgG1	3-53	5	ARGYPGGP	0	1-33	4	QQYDNL	0	0.18		
HK CV05-178		ASC	IgA2	3-23	3	AKDALGFCSGTSCYGEAFDI	19	1-5	2	QQYNSYPYT	10	0.07		
HL CV05-178		ASC	IgA2	3-23	3	AKDALGFCSGTSCYGEAFDI	19	2-23	3	CSYAGSSTWV	2	n.exp.		
HK CV05-181		ASC	IgG1	3-30-3	6	ARDLQYYDFWSGYLGTGPRYYYGMDV	0	3-20	1	QQYGSSPPWT	0	0.07		
HL CV05-182	5-3	ASC	IgG1	4-59	6	ARDRVSGGMDV	0	3-21	2	QVWDSDDHVV	1	n.exp.		
HK CV05-183		ASC	IgG1	3-30-3	6	ARDLRFLEWLFNVPYYYGMDV	0	1-9	2	QLNSYPYT	0	0.11		
HL CV05-183		ASC	IgG1	3-30-3	6	ARDLRFLEWLFNVPYYYGMDV	0	2-23	3	CSFAGGITLV	14	n.exp.		
HK CV05-185		ASC	IgM	3-15	4	TTDRTYDYVWGSYRDRDY	0	1-39	4	QQSYSTLPRT	1	0.06		
HK CV05-187		ASC	IgG2	3-73	4	TTIGSGYGFH	10	1-39	2	QQSYSTHT	1	n.exp.		
HL CV05-187		ASC	IgG2	3-73	4	TTIGSGYGFH	10	2-11	2	CSYGGTYVL	11	0.1		
HL CV05-189		ASC	IgG1	3-9	6	AKAHSDPNYDFWSPDYGMDV	1	2-14	2	SSYSTSSTKEV	5	0.10		
HL CV05-190		ASC	IgG1	3-30-3	4	ARGVYGDGSDY	1	3-21	1	QVWDSDDHLYV	1	0.08		
HK CV05-191		ASC	IgG2	3-11	6	ARDTSQSHMDV	15	2-30	2	MQGTHWPPYT	6	0.08		
HK CV05-192	5-1	ASC	IgG1	1-3	3	AREDTFSVFGVTRGNAYDV	26	3-20	1	QQYGVSPRT	20	0.11		
HL CV05-194		ASC	IgG1	3-74	1	ARDRHTYSLEYFQH	0	6-57	3	QSYDSSNQV	1	0.08		
HL CV05-195		ASC	IgG1	3-30	4	AKEGSKGWLQSSCYFDY	0	3-25	2	QSADSSGTQV	2	0.1		
HK CV07-102		ASC	IgG1	1-18	6	ARDLARVGWTVVWYGGMDV	2	2-30	1	MQGTHWPRT	0	n.exp.		
HL CV07-103		ASC	IgM	3-23	4	AKVYGSNTHTPVDY	5	2-8	2	SSYAGSNNVV	4	0.09		
HK CV07-104		ASC	IgG1	3-7	6	ARDAARYGMDV	24	1-39	2	QQSYSTPRT	10	0.09		
HK CV07-107		ASC	IgG3	3-23	6	AKDRRTMIVVITNKYYYGMDV	0	1-5	4	QQYNSYPLT	0	0.11		

mAb	Clonality	Source cell	Ig isotype	IGHV gene	IGHJ gene	CDR H3	SHM IGHV	IGKV/IGLV gene	IGKJ/IGLJ gene	CDR L3	SHM IGKV/IGLV	S1 reactivity (OD ratio)	RBD reactivity	Estimated IC <sub>50</sub> (ng/ml)
HL CV07-108		ASC	IgM	3-15	4	TTDADTSPVV	4	4-69	3	QTWDTGIRV	7	0.08		
HK CV07-110		ASC	IgM	3-48	4	ARSLRMG	7	3-20	1	HQYGSIPRT	12	n.exp.		
HK CV07-113		ASC	IgA1	4-59	6	ARASFKMGTYHYGMDV	13	1-27	3	QNYNSVPFT	12	0.08		
HK CV07-114		ASC	IgG1	1-2	4	TTLTAVVTPGLY	40	2-30	1	MQGTHWPRT	1	0.07		
HL CV07-118		ASC	IgM	3-15	3	TTDEQRNYCTSPNCRGGAFDI	7	4-69	3	QTWGTGIRV	7	n.exp.		
HK CV07-121		ASC	IgG1	4-39	5	MRQGDWNYSYYFDA	35	2-30	4	VQGTWLWPLT	12	n.exp.		
HK CV07-127		ASC	IgA1	4-39	6	ARHPLALITIFGVSRQYGMV	0	1-12	1	QQANSFPWT	1	0.1		
HL CV07-128		ASC	IgG2	3-30-3	4	ARELGTSGLTDS	23	2-14	3	LSHSTFTTPQWV	21	0.08		
HL CV07-129		ASC	IgG1	3-48	3	ASIASYDYVWGTNRPNDAFDI	17	2-23	1	CSYGGPRNLV	15	0.09		
HL CV07-132		ASC	IgM	4-4	4	ARDRQYRGSYNYFYDY	3	1-44	3	ATWDDSLNLRV	5	0.09		
HK CV07-133		ASC	IgG2	4-39	4	ARHQRPVTTFDIY	29	3-15	3	QHYKDWPPFT	19	0.08		
HK CV07-134		ASC	IgG1	3-23	6	AKVMRDDFWSGYNDYYGMDV	6	3-20	2	QQYGR	0	0.09		
HK CV07-136		ASC	IgG1	4-59	6	ARDNYSSRRYYYYYGMV	0	3-20	1	QQYSSPTWT	0	0.10		
HL CV07-137		ASC	IgM	4-30-4	5	ARLSMTTVTRGNWFDP	0	1-47	3	AAWDDSLSGWV	0	0.10		
HK CV07-138		ASC	IgA2	3-23	2	VKDFPFGGCTSTTNCDLFFAL	21	2-24	1	MQATQFPRA	11	n.exp.		
HK CV07-139		ASC	IgG2	4-59	5	AGYLRNDLDP	11	3-11	4	QQRSDWPLT	9	n.exp.		
HK CV07-140		ASC	IgA1	3-64	4	AREYYGLLTGYLDL	19	1-39	1	QSYSIPWT	24	0.08		
HK CV07-143	7-3	ASC	IgG1	3-23	4	AKEFSIGWGLFDS	17	3-11	5	QQRNNWPVT	13	n.exp.		
HK CV07-147		ASC	IgG1	1-2	6	ARDLYDILTGYMPMDV	4	3-11	5	QQRGNWPIT	4	n.exp.		
HK CV07-151		ASC	IgG1	1-58	3	AADPGGVGYCSGGSCYRAFDI	1	3D-15	4	QQYNNWPPALT	0	0.09		
HL CV07-152		ASC	IgG1	1-69	3	ARLRVPLTAHDAFDI	0	1-40	3	QSYDSSVGV	3	0.09		
HL CV07-154		ASC	IgG1	1-69	6	ARAYCSGGSCSYYYGMDV	2	3-1	2	QAWDSSTA	0	0.11		
HK CV07-155		ASC	IgM	4-59	6	ARVPREWLSPLYYG	2	1-5	1	QQYNSYQWT	0	0.09		
HL CV07-156		ASC	IgG1	3-9	4	VKDNARTRRGSFDY	15	2-23	1	CSYAGSNTYV	13	0.09		
HL CV07-159		ASC	IgG2	3-48	3	AREGELSNYDAFDI	18	2-11	1	CSYAGTHSYV	9	0.08		
HK CV07-161		ASC	IgG1	3-30	4	AKEGSKGWLQSSCYFDY	1	2-28	5	MQAFEPPIIT	40	0.12		
HK CV07-163		ASC	IgM	3-33	4	ARDWAVAGNFDY	14	3-20	5	QQYGASPPIT	7	0.09		
HL CV07-164		ASC	IgA1	1-46	4	ARDGSHWDFDY	22	2-14	3	SSYVSSDAWV	4	0.09		
HL CV07-165		ASC	IgM	3-53	4	ARRAASGNWFDY	9	2-23	3	CSYLGSATYV	19	n.exp.		
HK CV07-166		ASC	IgG1	1-18	6	ARDTWDIVPAASAYYGMV	21	2-28	2	MQALQHT	1	n.exp.		
HK CV07-172		ASC	IgM	3-15	4	TTDRTYDYVWGSYRYRDI	0	1-39	1	QQTFSPPWT	27	0.07		
HK CV07-173		ASC	IgM	3-30	6	SKGFLEWLLRRYYYGMDV	3	1-9	3	QQLNSYPFT	0	0.07		
HK CV07-176		ASC	IgA1	5-51	6	ARHFGGSGSYNGHWIPAYYYHGMV	7	2-28	4	MQARQTPPLT	4	n.exp.		
HL CV07-176		ASC	IgA1	5-51	6	ARHFGGSGSYNGHWIPAYYYHGMV	7	2-8	2	SSYAGSTNLV	4	n.exp.		
HK CV07-178		ASC	IgG2	4-31	3	ARDRTMVVWNAFDI	17	1-39	1	QQSHSPSRT	13	0.18		
HL CV07-179		ASC	IgA1	3-7	5	ARESRLGIAIFDRRLRSWFGA	0	2-14	1	SSYTSSSTRV	0	n.exp.		
HK CV07-180		ASC	IgM	3-15	4	TTQHYDFWGSNYKPPAF	12	2-28	5	MQALQTLT	3	0.11		
HL CV07-181		ASC	IgA1	3-33	4	ARDEAAEYFYDY	1	3-25	3	QSADSSGTFWV	1	0.11		
HK CV07-183		ASC	IgG1	3-30	4	AKEGSKGWIQNSCYFDY	12	4-1	1	QQYYSTPPT	3	n.exp.		
HK CV07-185		ASC	IgA1	3-23	4	VKDPNWANGY	30	2-30	4	VQGTHWPLT	16	n.exp.		
HK CV07-186		ASC	IgA1	1-46	4	AKGRSTIFGVIVNQGDYDY	9	1-27	4	QKYNAPL	4	0.10		
HK CV07-189		ASC	IgG1	3-23	4	AKDPHDFWGSNYFYDY	5	1D-12	4	QQANSFPLT	0	0.06		
HK CV07-190		ASC	IgM	4-31	3	ARDRGTIFGVVIDAFDI	1	3-20	4	QQYSSPLT	0	0.05		
HK CV07-191		ASC	IgG1	1-18	6	SREGDLTIFGSVTNAYYFGMDF	3	1-39	5	QQSYSTPIT	1	n.exp.		
HL CV07-196	7-1	S1-MBC	IgM	1-2	4	ARDLIGIVAGNLDH	4	2-8	3	SSYAGSNNWV	2	2.06	++	>250
HK CV07-199		S1-MBC	IgM	4-59	5	ARDRDSSGWYPNWFDP	2	1D-16	1	QQYNSYPRT	0	0.07		
HL CV07-200	7-2	S1-MBC	IgG1	1-2	6	ARGPFYDNSGTLGGLDV	5	2-14	1	SSYTSSSTYV	1	8.57	++	25
HL CV07-201	7-4	S1-MBC	IgM	1-2	6	ATDRLVNTGVYTTGSMDV	8	2-23	1	CSYGGSSDYV	2	4.03	++	>250
HK CV07-202		S1-MBC	IgG1	3-53	6	ARDLYYYGMDV	4	1-9	4	QQLNNSYVT	2	8.87	++	25-250
HL CV07-203		S1-MBC	IgM	1-2	6	ARKQQPSSLSYYYGMDV	1	1-40	3	QSYDSSLSGSWV	3	0.06		



mAb	Clonality	Source cell	Ig isotype	IGHV gene	IGHJ gene	CDR H3	SHM IGHV	IGKV/IGLV gene	IGKJ/IGLJ gene	CDR L3	SHM IGKV/IGLV	S1 reactivity (OD ratio)	RBD reactivity	Estimated IC <sub>50</sub> (ng/ml)	
HL CV07-204	S1-MBC	IgM	4-39	6	ALCGYSYGSNYYYYGMDV	0	6-57	3	QSYDSSIWV	2	0.09				
HK CV07-205	S1-MBC	IgM	3-23	4	AKEYGYDSSGSGGDY	0	1-39	1	QQSYSTPNT	0	0.07				
HL CV07-205	S1-MBC	IgM	3-23	4	AKEYGYDSSGSGGDY	0	2-23	3	CSYAGSSTWV	2	n.exp.				
HK CV07-206	S1-MBC	IgM	1-2	6	AREGYDFWVSGYYTVYYYGMDV	0	1-5	1	QQYNSYWT	9	n.exp.				
HL CV07-206	S1-MBC	IgM	1-2	6	AREGYDFWVSGYYTVYYYGMDV	0	2-14	3	SSYTSSTRV	1	3.98	++	250		
HL CV07-208	7-2	S1-MBC	IgM	1-2	6	ARGPFYDSSGTLGGMDV	3	2-14	1	SSYTSRNTYV	5	n.exp.			
HK CV07-209	S1-MBC	IgG1	3-11	4	ARDGVIPPRFDY	2	1-33	4	QQYDNLPLT	1	12.06	++	<25		
HL CV07-210	S1-MBC	IgM	3-21	4	VSSGNRYRFHY	8	2-14	1	SSYMSSTPYV	4	0.18				
HL CV07-213	7-5	S1-MBC	IgM	1-8	4	ARGPSWNGYYYYFDY	6	1-44	2	ASWDDRLNGVV	7	0.1			
HK CV07-214	S1-MBC	IgG1	6-1	3	AREENAFDI	0	3-15	2	QQYSNLLYT	4	7.69	++	>250		
HK CV07-215	S1-MBC	IgM	3-48	3	AREGHAFDI	2	3-20	1	QQYGSPPSWT	1	0.08				
HK CV07-216	S1-MBC	IgM	3-7	4	VAWGTPLGTSENN	16	2-30	2	MQHTHPHT	11	0.08				
HL CV07-217	7-5	S1-MBC	IgM	1-8	4	ARGPSWNGYYYYFDY	6	1-44	2	ASWDDSLNGVV	8	0.12			
HL CV07-218	S1-MBC	IgM	3-23	4	AKRMGGNRFNPPVEY	12	1-40	3	HSYDSSLASV	6	n.exp.				
HK CV07-219	S1-MBC	IgG2	3-11	6	ARDGIGLWDDSYGYLDV	15	2-30	2	MQGAHWPPYT	10	3.68	++	>250		
HL CV07-221	7-4	S1-MBC	IgM	3-30	6	AKKAGYSSGWYTDYYNGMDV	1	1-40	3	QSYDSSLRGV	4	0.15			
HL CV07-222	S1-MBC	IgG1	1-2	3	ARGPYDSSGSLGAFDI	5	2-23	1	CSYAGGTSYV	2	12.03	++	<25		
HL CV07-223	7-5	S1-MBC	IgM	1-8	4	VRGPSWNGYYYYFDY	6	1-44	2	ASWDDSLNGVV	3	0.08			
HL CV07-224	S1-MBC	IgM	5-51	6	ARLGPYSSSSNGMDV	2	2-23	3	CSYAGSSTRV	3	0.08				
HK CV07-225	S1-MBC	IgG1	4-31	6	ARDTPPGYNWNGPYGMDV	9	3-15	2	QQYNNWPPGYT	4	4.78	++	>250		
HL CV07-226	S1-MBC	IgM	3-30	6	AKKAGYSSGWYTDYYNGMDV	1	2-8	3	SSYASNRG	41	n.exp.				
HL CV07-230	S1-MBC	IgM	3-9	4	AKEISGYFDY	7	4-69	3	QTWGTGIHVV	14	0.08				
HL CV07-231	7-4	S1-MBC	IgM	3-30	6	AKKAGYSSGWYTDYYNGMDV	1	1-40	3	QSYDSSLRGV	4	0.07			
HL CV07-235	S1-MBC	IgM	3-23	6	AKSTYGDYYYYGMDV	7	2-14	3	NSYTSNSSLGV	8	6.16	++	>250		
HK CV07-236	S1-MBC	IgM	3-53	4	AREYSSGWYDY	0	3-15	4	QQYNNWPLT	3	0.09				
HL CV07-237	7-2	S1-MBC	IgA1	1-2	6	ARGPFYDSSGTLGGMDV	3	2-14	1	SSYTSSTYV	0	5.58	+	n.t.	
HL CV07-238	S1-MBC	IgM	1-8	6	ARTNWNYYYYYGGMDV	0	1-44	1	AAWDDSLNGYV	2	0.09				
HL CV07-239	S1-MBC	IgM	4-34	3	ARGRWYHDNNGYRSDAFDV	17	1-44	3	AAWDDSLNEV	9	0.07				
HL CV07-241	S1-MBC	IgM	3-74	4	ITSMFNNGFY	7	2-11	2	SSYAGSYTV	7	0.08				
HL CV07-242	S1-MBC	IgM	3-15	5	TTLWRLDV	46	7-46	3	LLHTDSRV	11	n.exp.				
HL CV07-249	7-1	S1-MBC	IgM	1-2	4	ARDLIGVAGNLDH	1	2-8	3	SSYAGSNWV	3	2.87	+	n.t.	
HL CV07-250	S1-MBC	IgG1	1-18	6	AGSDNYGFPYNGMDV	17	2-8	2	SSYAGNDFV	16	8.27	++	25		
HK CV07-251	7-3	S1-MBC	IgM	3-23	4	AKEFSIGWGLFDY	9	3-11	5	QQRNNWVPT	8	8.79	++	25-250	
HK CV07-252	S1-MBC	IgG1	1-46	6	ARDKHWNNANYYYYGMDV	1	1-5	4	QQYNSYL	2	6.03	++	>250		
HL CV07-254	S1-MBC	IgM	1-2	4	ARDQGAALVGHNSY	10	2-23	2	CSYAGSSTWV	3	6.71	++	>250		
HL CV07-255	S1-MBC	IgG1	1-2	4	ARDSRFSYVNGEFDY	3	2-23	3	CSYAGHSTWV	5	9.54	++	25		
HL CV07-262	S1-MBC	IgG1	1-2	6	ARVGWYDFGTGPDYYYYGMDV	6	2-23	1	CSYAGTSTFV	3	10.2	++	<25		
HK CV07-263	S1-MBC	IgG1	1-2	6	ADSGYWGSHYYYGMDV	3	2D-29	1	MQSIQLPLT	0	7.87	++	25-250		
HL CV07-264	7-1	S1-MBC	IgA2	1-2	4	ARDLIGVAGNLDH	1	2-8	3	SSYAGSNWV	2	7.08	++	250	
HK CV07-265	S1-MBC	IgG1	3-48	6	ARRRYSSWYYYYGMDV	2	1-9	4	QQLNSYPLT	0	6.41	-	n.t.		
HL CV07-266	7-4	S1-MBC	IgG1	1-2	6	ATDRLVNTGVYTTGSMV	8	2-23	1	CSYGGSSDYV	2	4.62	++	>250	
HL CV07-267	7-6	S1-MBC	IgA1	1-2	6	ARVFGPGLDCSSTCYTYGMDV	2	2-23	3	CSYAGSSWV	1	8.47	++	250	
HL CV07-270	S1-MBC	IgG3	3-11	5	ARARGSSGWYRIGTRWGNWFDP	2	2-14	2	SSYTSSTNVV	0	8.53	++	25-250		
HL CV07-271	S1-MBC	IgA1	1-2	6	ARVPFAYCSSTSCDRGTPYYYYGMDV	0	2-14	2	SSYTSSTLV	3	8.28	++	>250		
HK CV07-272	S1-MBC	IgM	3-64	4	ARGLDNNGYSGY	16	3-20	1	QQYGSPPRT	5	0.08				
HL CV07-274	7-7	S1-MBC	IgM	1-2	4	ARDQKNDILTGLGDY	4	2-8	3	SSYAGSNWV	1	3.97	++	>250	
HL CV07-275	S1-MBC	IgG1	3-66	4	ARDYYDSSGYSSGGLGY	0	2-8	1	SSYAGSNFV	0	4.51	++	>250		
HL CV07-280	7-2	S1-MBC	IgA1	1-2	6	ARGPFYDSSGTLGGMDV	2	2-14	1	SSYTSSTYV	0	7.29	++	25-250	
HL CV07-281	7-2	S1-MBC	IgM	1-2	6	ARGPFYDSSGTLGGMDV	2	2-14	1	SSYTSSTYV	0	5.07	+	n.t.	
HL CV07-283	7-2	S1-MBC	IgA1	1-2	6	VRGPFYDSSGTLGGMDV	7	2-14	1	SSYTSSTYV	2	9.89	++	25	

mAb	Clonality	Source cell	Ig isotype	IGHV gene	IGHJ gene	CDR H3	SHM IGHV	IGKV/IGLV gene	IGKJ/IGLJ gene	CDR L3	SHM IGKV/IGLV	S1 reactivity (OD ratio)	RBD reactivity	Estimated IC <sub>50</sub> (ng/ml)
HL CV07-284	S1-MBC	IgM	5-51	6	ASGGDYPYGMVDV	5	1-44	3	AAWDDSLSAWV	1	0.87	++	>250	
HL CV07-285	7-2	S1-MBC	IgA1	1-2	6	ARGPFYYDNSGLGGLDV	5	2-14	1	SSYSSSTYV	1	9.3	++	25
HL CV07-286	S1-MBC	IgG1	3-9	6	AKGGRYCSGTNCEYFFAMDV	8	2-8	2	SSYAGSNNNVV	3	0.09			
HK CV07-287	S1-MBC	IgG1	1-58	3	AAPYCSSTNCDYAFDI	0	3-20	1	QQYGSSPWT	0	9.25	++	25-250	
HK CV07-289	S1-MBC	IgM	1-2	6	ARGAAMVTGYTYYYGLDV	3	3-20	5	QQYGSSPIT	2	0.07			
HL CV07-290	7-7	S1-MBC	IgM	1-2	4	ARDQKNDILTGLGDY	0	2-8	3	SSYAGSNNWV	0	3.02	++	>250
HL CV07-292	7-7	S1-MBC	IgM	1-2	4	ARDQKNDILTGLGDY	3	2-8	3	SSYAGSNNWV	0	7.92	++	250
HK CV07-293	S1-MBC	IgM	3-11	6	ARCNGGGACFYGMVDV	10	4-1	5	QQYYSTLT	3	0.07			
HL CV07-293	S1-MBC	IgM	3-11	6	ARCNGGGACFYGMVDV	10	2-14	3	SSYTSSTWV	4	0.07			
HL CV07-294	7-2	S1-MBC	IgM	1-2	6	ARGPFYDSSGLGGMVDV	2	2-14	1	SSYSSSTYV	0	5.69	++	>250
HL CV07-297	S1-MBC	IgM	3-53	4	ARRSASGWNFDY	13	2-8	3	SSYAGSNNLV	8	0.08			
HL CV07-299	S1-MBC	IgM	5-51	4	ATSHGYSGYELGY	9	2-14	3	SSYSSSTWV	29	n.exp.			
HK CV07-301	S1-MBC	IgG1	1-2	6	ARVDTTGTTFWLYYYGMDV	2	2D-29	3	N/A	0	0.17			
HL CV07-301	S1-MBC	IgG1	1-2	6	ARVDTTGTTFWLYYYGMDV	0	2-23	3	CSYAGSSTWV	2	n.exp.			
HK CV07-302	S1-MBC	IgA1	3-9	6	AKDKGPYYYYGMDV	0	2D-29	1	MQSIQLPQT	0	1.51	++	250	
HL CV07-303	7-1	S1-MBC	IgM	1-2	4	ARDLGIGVAGNLDH	4	2-8	3	SSYAGSNNWV	3	4.71	++	250
HL CV07-304	7-6	S1-MBC	IgA1	1-2	6	ARVFGPGLDCSSTSCYTYGMDV	1	2-23	3	CSYAGSNSWV	2	8.08	++	>250
HL CV07-305	7-1	S1-MBC	IgM	1-2	4	ARDLGIGVAGNLDH	2	2-8	3	SSYAGSNNWV	2	0.93	++	>250
HK CV07-306	S1-MBC	IgA1	1-2	4	ARGTLYDILTGPSPKLDY	0	1-39	1	QQSYSTPWT	0	8.25	++	250	
HL CV07-307	7-2	S1-MBC	IgA2	1-2	6	ARGPFYYDNSGLGGLDV	5	2-14	1	SSYSSSTYV	1	9.27	++	25
HL CV07-309	7-2	S1-MBC	IgM	1-2	6	ARGPFYYDNSGLGGLDV	5	2-14	1	SSYSSSTYV	1	8.62	++	25-250
HL CV07-310	7-2	S1-MBC	IgA1	1-2	6	ARGPFYDSSGLGGMVDV	3	2-14	1	SSYSSSTYV	0	5.11	+	n.t
HL CV07-312	S1-MBC	IgM	1-2	6	ARIPFVVSTPGQYYYGMDV	6	2-14	3	ISYSSSTWV	1	0.18			
HL CV07-313	7-4	S1-MBC	IgA1	1-2	6	ATDRLVNTGVYTTGSMVDV	9	2-23	1	CSYGGSSDYV	2	0.09		
HK CV07-315	S1-MBC	IgG1	3-9	6	AKDFLWDLHPPRYGMDV	0	1-39	2	QQSYSTHA	1	0.16			
HL CV07-315	S1-MBC	IgG1	3-9	6	AKDFLWDLHPPRYGMDV	0	1-51	3	GTWDSNLNGV	1	11.4	++	25	
HL CV07-316	7-2	S1-MBC	IgA1	1-2	6	ARGPFYDSSGLGGMVDV	2	2-14	1	SSYSSSTYV	1	3.12	+	n.t
HL CV07-317	7-7	S1-MBC	IgM	1-2	4	ARDQKNDILTGLGHY	0	2-8	3	SSYAGSNNWV	0	2.53	++	>250
HK CV07-319	S1-MBC	IgM	1-2	5	ARGPFFFEVVVAEFGWFDP	28	3-15	5	QQYNNWPPIT	1	n.exp.			
HL CV07-319	S1-MBC	IgM	1-2	5	ARGPFFFEVVVAEFGWFDP	28	2-8	1	SSYAGSNNYV	0	n.exp.			
HL CV07-323	7-6	S1-MBC	IgA1	1-2	6	ARVFGPGLDCSSTSCYTYGMDV	0	2-23	3	CSYAGSSWV	1	7.39	++	>250
HL CV07-324	7-2	S1-MBC	IgA1	1-2	6	ARGPFYDSSGLGGMVDV	4	2-14	1	SSYSSSTYV	3	11.02	++	25-250
HK CV23-101	S1-MBC	IgM	3-30	4	ARDWEYYSGSKAFDY	9	1-13	4	QHFNSYPLT	9	4.33	++	>250	
HL CV23-103	S1-MBC	IgA1	1-2	4	N/A	47	2-14	2	SSYTRSTAVV	19	n.exp.			
HL CV23-113	S1-MBC	IgM	5-51	4	ATTRGYSYEFAY	11	2-8	3	SSYAGSNNFPWV	3	n.exp.			
HK CV23-114	S1-MBC	IgM	4-31	5	ARDLGRSDFGSGVGVVIDP	10	3-15	1	QQYHNWPPWT	5	n.exp.			
HL CV23-115	S1-MBC	IgM	1-2	3	ARGYYDILIGYATTHDAFDL	8	2-14	3	SSYDSSSTWV	6	n.exp.			
HK CV23-116	S1-MBC	IgM	3-21	6	ARASLVTMVRGAGNYMDV	0	3-11	5	QQRSNWPLT	0	0.11			
HL CV23-116	S1-MBC	IgM	3-21	6	ARASLVTMVRGAGNYMDV	0	2-23	3	CSYAGSRV	2	0.09			
HL CV23-121	S1-MBC	IgM	1-2	4	ARELGSWDGRFDY	0	2-23	3	CSYAGSSTWV	0	0.10			
HK CV23-126	S1-MBC	IgM	4-59	6	ARDTTSYCSGGSCYNYGMDV	7	2-28	3	MQALQTPRT	3	0.07			
HL CV24-198	24-1	S1-MBC	IgA1	1-2	3	ARDLAYSMVRGISGI	7	2-23	3	CSYAGSNTWV	7	5.48	++	250
HL CV24-201	24-1	S1-MBC	IgA1	1-2	3	ARDLAYSMVRGISGI	7	2-23	3	CSYAGSNTWV	9	5.79	++	>250
HK CV24-220	S1-MBC	IgA2	3-48	4	ARDRGSWLSLDESDFDH	15	1-39	2	QQKSIPYT	17	n.exp.			
HL CV24-223	24-5	S1-MBC	IgM	4-39	4	ARLRWLRGEFDY	0	6-57	3	QSYDSSSTYV	0	8.83	++	>250
HL CV24-226	24-5	S1-MBC	IgM	4-39	4	ARLRWLRGEFDY	0	6-57	3	QSYDSSSTYV	0	8.77	++	>250
HL CV24-236	S1-MBC	IgM	3-49	4	IRGGYGGNSGFYD	5	1-51	2	GTWDSLSAVV	3	0.15			
HL CV24-243	ASC	IgM	3-7	4	ARLYSGNYFDY	6	4-69	3	QTWDTAIWV	14	n.exp.			
HK CV24-247	ASC	IgA1	3-48	5	ARGFYDILTGYYSFHFIDL	16	1-5	1	QQYNTYWT	7	0.35			
HK CV24-248	24-2	ASC	IgG1	3-33	6	ARREGVADYYYYGMDV	8	1-6	1	LQVYNYPWT	6	0.09		

mAb	Clonality	Source cell	Ig isotype	IGHV gene	IGHJ gene	CDR H3	SHM IGHV	IGKV/IGLV gene	IGKJ/IGLJ gene	CDR L3	SHM IGKV/IGLV	S1 reactivity (OD ratio)	RBD reactivity	Estimated IC <sub>50</sub> (ng/ml)
HL CV24-249		ASC	IgG1	1-18	6	AREYDYSNPNYYYYYGM DV	0	3-27	3	YSAADNM GV	1	0.08		
HK CV24-252		ASC	IgG1	3-74	6	VRVSGPFHDYFLYAMD V	19	3-20	1	QHYSAA TWT	14	0.09		
HL CV24-253	24-3	ASC	IgA1	1-2	4	ARVFHGVITPF DY	12	5-37	2	MIWPSSA VV	7	0.07		
HK CV24-255		ASC	IgG1	4-34	4	ARGRLGFEELFRGVFF YFYDY	21	1-39	2	QQTFNSP RT	22	0.07		
HK CV24-256	24-4	ASC	IgM	3-49	5	TRAQEEKITMIRRIIS W F DP	5	3-20	5	QQYGSSP IT	6	0.1		
HL CV24-260		ASC	IgG1	4-59	6	ARLLKSCTGGICQTYF YAMD V	21	1-40	1	QSYDGLS ESASAV	20	0.1		
HK CV24-262		ASC	IgA1	4-31	4	ARGTTYTIFGVVISPF DY	0	3-20	4	QQYGSSP LT	0	0.09		
HK CV24-265		ASC	IgG1	4-34	5	ARGAPGT	30	1-5	2	QHYSTFP YT	15	0.1		
HK CV24-268		ASC	IgG1	3-9	4	TTGYCRSNCLTFYAF	20	1-39	2	QQSYRAP VT	13	0.08		
HL CV24-269		ASC	IgM	4-31	6	ARDYFGRSGSGSSLY YYYGMD V	0	3-1	2	QAWDSST V	0	5.39	-	n.t.
HK CV24-271		ASC	IgG1	3-21	4	ARVAAGQKYFYDY	0	1-9	4	QQLNS	0	0.12		
HL CV24-275		ASC	IgG1	3-30	6	AKVANVFMLYPRGSW GMDV	14	1-47	3	AAWDDSL SGWV	14	0.09		
HK CV24-280		ASC	IgG1	3-48	6	AAGSSTSPSPV	0	3-15	1	QQYNNWP RT	0	0.16		
HK CV24-282		ASC	IgG1	3-23	6	AKDRGRRRLTHLGVAP DV	23	1-39	2	QQSYTPPY T	19	0.15		
HK CV24-283		ASC	IgM	3-66	4	CGGYGSSWYLDY	20	3-11	2	QQRSNWP YT	10	0.15		
HL CV24-284		ASC	IgG1	4-31	4	ARGGLSSRNGGNRSY SSSSFLPGRQDY	0	2-14	1	SSYTSSST LYV	1	0.15		
HL CV24-285		ASC	IgM	5-51	4	ARFLSFVTSPTRYDY	6	2-14	1	SSYTSSST LV	8	0.14		
HK CV24-286		ASC	IgG1	1-69	3	ARHPLSGYAFDV	22	3-20	2	QQYGSSPY T	13	0.19		
HK CV24-287		ASC	IgM	3-23	3	AKDRSGGILAGSGGAL DI	26	1-5	1	QQYSSYS RT	14	0.16		
HL CV24-290		ASC	IgG1	4-39	4	ARASEDISLERAYNYGL TIDF	10	3-9	2	QVWDSST VV	6	0.16		
HL CV24-293		ASC	IgA1	3-7	6	ARENYDSSGYYYYAY YYYGMD V	0	3-25	1	QSADSSGT YV	3	n.exp.		
HK CV24-294		ASC	IgM	3-9	4	ARGDLGIRYFDY	5	3-15	5	QQYNNWP PIT	1	n.exp.		
HL CV24-294		ASC	IgM	3-9	4	ARGDLGIRYFDY	5	2-23	3	CSYAGSST WV	2	n.exp.		
HK CV24-296		ASC	IgG3	1-18	1	N/A	11	4-1	2	QQYHSTPP A	4	n.exp.		
HL CV24-296		ASC	IgG3	1-18	1	N/A	11	2-23	3	CSYAGSST WV	2	n.exp.		
HK CV24-298		ASC	IgG1	3-33	3	ARGWGGDGYTVDAFD V	19	2-28	2	MQUALQPP YI	9	n.exp.		
HK CV24-301		ASC	IgG1	1-46	5	ARSLYSGSYGAYNWF DP	19	3-11	4	LQRINWLT	13	n.exp.		
HK CV24-309		ASC	IgG1	4-61	6	AREQVLDPLYYGIDV	29	1-39	2	QQSYSTHT	1	n.exp.		
HL CV24-309		ASC	IgG1	4-61	6	AREQVLDPLYYGIDV	29	3-1	2	QAWDSST VI	23	n.exp.		
HL CV24-310	24-3	ASC	IgG1	1-2	4	ARVFHGVITPFDF	19	5-37	2	MIWPSSD VV	4	n.exp.		
HL CV24-311		ASC	IgG1	1-2	4	ARGADIFITFGVVIKEN DY	0	2-18	2	SSYTSSST LV	2	n.exp.		
HL CV24-314		ASC	IgM	3-30	4	ARGKNYGYSDDL FQHFDY	3	7-43	3	LLHYGSSQL GV	12	n.exp.		
HK CV24-316		ASC	IgG1	1-69	6	ARALGLSGHGMDV	29	1-39	2	QHSYSTP HT	17	n.exp.		
HL CV24-317		ASC	IgG1	4-4	3	AKESWLELWLQAGFDI	16	2-11	2	CSYGGSYTF VV	12	n.exp.		
HL CV24-319		ASC	IgG1	1-46	6	ARDLWMEYENDSGIQKTAD QGMDV	16	3-1	3	QAWDINTV V	17	n.exp.		
HK CV24-321		ASC	IgM	3-33	3	ARDMVRGPNDASDI	10	1-12	4	QQANSFPL T	4	n.exp.		
HL CV24-322		ASC	IgG1	4-39	4	ARQRTHTIFGVVHF DY	1	3-25	1	QSADSSGT YDV	3	n.exp.		
HK CV24-323	24-4	ASC	IgM	3-49	5	TRAQEEKITMIRRIIS W F DP	5	3-20	5	QQYGSSP IT	6	n.exp.		
HK CV24-325	24-4	ASC	IgM	3-49	5	TRAQEEKITMIRRIIS W F DP	5	3-20	5	QQYGSSP IT	8	n.exp.		
HK CV24-329		ASC	IgM	3-33	3	ARDMVRGPNDASDI	10	3-15	5	QQYNNWP PV	3	n.exp.		
HK CV24-330	24-4	ASC	IgM	3-49	5	TRAQEEKITMIRRIIS W F DP	5	3-20	5	QQYGSSP IT	11	n.exp.		
HL CV24-331		ASC	IgG1	3-23	6	AKEVPDIIVAVAVGMD V	21	1-47	2	ASWDDSL SGVL	12	n.exp.		
HL CV24-332		ASC	IgG1	1-2	6	ARETRETYYDILTGYFF YFYFGMD V	9	1-51	2	GTWDGSL SAAV	11	n.exp.		
HL CV24-333		ASC	IgM	3-15	4	SSDLPKWGSGMADY	13	8-61	3	VLYMGSDI WA	12	n.exp.		
HK CV24-336	24-4	ASC	IgM	3-49	5	TRAQEEKITMIRRIIS W F DP	5	3-20	5	QQYGSSP IT	8	n.exp.		
HK CV24-344	24-2	ASC	IgG1	3-33	6	ARREGVADYSYSCGMD V	10	1-6	1	LQVYNYPW T	11	n.exp.		
HK CV24-346		ASC	IgG1	1-69	3	ARSDSSGGYYLKEENDAF DI	0	2-30	2	MQGTHWRE YT	1	n.exp.		
HL CV24-347		ASC	IgG3	1-2	6	ARDRLYCSSTSCYTPY YYYGYGMD V	0	3-25	3	QSADSSGT YGV	3	n.exp.		
HL CV38-102		S1-MBC	IgG1	3-23	2	AKVETRGGVFDL	1	3-1	2	QAWDSST VV	1	8.7	-	n.t.
HK CV38-103		S1-MBC	IgA1	3-11	4	ARDWNLSGGYGGGR	1	1-16	4	QQYNSYPL T	0	5.84	++	>250

mAb	Clonality	Source cell	Ig isotype	IGHV gene	IGHJ gene	CDR H3	SHM IGHV	IGKV/IGLV gene	IGKJ/IGLJ gene	CDR L3	SHM IGKV/IGLV	S1 reactivity (OD ratio)	RBD reactivity	Estimated IC <sub>50</sub> (ng/ml)
HK CV38-105		S1-MBC	IgG1	3-74	6	ARQRVARRRGFGESPFYYGLDV	22	1-6	1	LQNYNFPRT	7	0.26		
HL CV38-107	38-1	S1-MBC	IgA1	1-2	4	ARDGAQYILTGFDFY	0	2-8	1	SSYAGSNNYV	0	0.58	+	n.t.
HK CV38-113		S1-MBC	IgG1	3-53	4	ARGGRLADAAGDY	1	1-33	2	QQYDNLPSWT	1	11.47	++	25
HK CV38-114		S1-MBC	IgM	5-51	4	ARAGNDNSLDY	1	1-39	2	QQSYTTPYT	18	0.17		
HL CV38-114	38-4	S1-MBC	IgM	5-51	4	ARAGNDNSLDY	1	9-49	3	GADHGSGSNFVQKV	1	8.13	++	>250
HL CV38-115		S1-MBC	IgG1	3-7	5	ARDLYYYDSSNGVNWFD	3	1-40	1	QSYDSSLGSGYV	1	8.04	++	n.t.
HL CV38-117		S1-MBC	IgG1	4-30-4	4	ARVTRIIYSGSYCFDY	0	2-23	2	CSYVGSSTFV	2	9.55	++	>250
HK CV38-118		S1-MBC	IgA1	4-59	4	ARAWSSSWYLDY	3	3-11	4	QQRSNWPPVT	0	0.51	+	n.t.
HL CV38-119		S1-MBC	IgA1	4-4	4	ARAWNFDY	0	2-23	3	CSYAGSSNWV	1	5.56	++	>250
HL CV38-122		S1-MBC	IgG1	3-23	3	AKVLDI	0	2-14	1	SSYTSSTPYV	2	n.exp.		
HK CV38-124		S1-MBC	IgG1	4-59	6	ATYYYDSSGYPYGM	1	1-9	3	QLNSYPG	3	6.07	++	>250
HL CV38-125	38-4	S1-MBC	IgG1	5-51	4	ARHQYSSSSLGY	1	9-49	3	GADHGSGSNFVYM	1	8.53	++	>250
HK CV38-127		S1-MBC	IgG1	3-33	4	ARDPEIVVGGVDY	0	2-30	2	MQGTHWPYT	0	3.45	++	>250
HK CV38-128		S1-MBC	IgA1	3-11	4	ARDWNLSGYGGGR	0	1-39	2	QQSYTTPYT	18	0.15		
HK CV38-129		S1-MBC	IgG1	4-31	3	ARDQGASASWDAFDI	0	3-20	4	QQYGSSTL	0	2.24	++	>250
HK CV38-131		S1-MBC	IgA1	3-11	4	ARDHSVRFLEWLLPY	0	1-9	1	QLNSYPWT	3	1.93	+	n.t.
HK CV38-132		S1-MBC	IgG1	4-31	4	ARAERSITIFGVVTSAFDY	1	4-1	2	QQYYSTPYT	0	1.24	+	n.t.
HK CV38-134		S1-MBC	IgG1	4-34	4	ASSGWYYPDY	3	3-20	4	QQYGSSPNT	0	7.98	++	>250
HL CV38-135		S1-MBC	IgG1	3-23	3	AKVTGLGNAFDI	3	3-1	2	QAWDSSTV	0	7.19	-	n.t.
HL CV38-136		S1-MBC	IgG1	4-4	5	ARSSGRGRVVALGSDP	1	2-23	3	CSYAGSSTWV	0	8.52	-	n.t.
HK CV38-139		S1-MBC	IgG1	3-53	4	ARGHYDLFDY	3	1-9	3	QLNSYPPGT	0	8.33	++	25-250
HK CV38-140		S1-MBC	IgA1	4-31	4	ARAYDSSGYYPDY	0	1-39	4	QQSYSTLT	0	2.56	++	>250
HK CV38-142		S1-MBC	IgG1	5-51	4	ARIRGVYSSGWIGGDY	4	1-39	1	QQSYSTPRQWT	0	9.39	++	25
HL CV38-143	38-1	S1-MBC	IgM	1-2	4	ARDGAQYILTGFDFY	0	2-8	1	SSYAGSNNYV	0	2.30	+	n.t.
HK CV38-146		S1-MBC	IgG1	1-69	5	ARAATYYYDSSGYTPNWFDP	1	1-39	2	QQSYSTLYT	0	2.17	++	>250
HL CV38-147		S1-MBC	IgG1	3-9	4	AKDRRIAVAGTGEDYFDY	4	3-21	2	QVWDSDDQV	1	11.7	++	250
HL CV38-148		S1-MBC	IgG1	3-66	4	ARSAPLVGAYSGIYFDY	2	9-49	2	GADHGSGSNFV	1	7.26	++	>250
HK CV38-149	38-3	S1-MBC	IgM	3-9	4	AKNRVAGTIFGVGPFDY	0	1-6	4	LQDNYPLT	1	0.73	-	n.t.
HK CV38-150		S1-MBC	IgG1	3-30	3	AKSQWLVRHAFDI	0	2D-29	1	MQSIQLWT	0	11.04	-	n.t.
HL CV38-156		S1-MBC	IgG1	4-59	4	ARFSYYYDSSGYDFDY	0	2-23	3	CSYAGSSWV	3	0.42		
HK CV38-158		S1-MBC	IgM	3-15	6	TTDRWFQELFSAYYYYGMDV	0	3-11	3	QQRSNWPPIFT	0	0.17		
HL CV38-159		S1-MBC	IgG1	1-2	4	ARGNTVFWSGPPLDY	0	2-14	1	SSYTSSTYV	0	4.27	+	n.t.
HL CV38-160		S1-MBC	IgG1	3-23	3	AKVAGRGNAFDI	3	7-43	2	LLYGGAL	3	n.exp.		
HK CV38-165		S1-MBC	IgG3	4-4	4	ARRSLGNYDSSGYDH	1	3-15	5	QQYNNWPPAIT	1	5.09	-	n.t.
HL CV38-165		S1-MBC	IgG3	4-4	4	ARRSLGNYDSSGYDH	1	1-44	1	AAWDDSLNGYV	0	0.15		
HL CV38-173		S1-MBC	IgG3	3-30-3	4	ARDYGGYNYN	4	3-1	2	QAWDSSTV	0	9.92	-	n.t.
HK CV38-177	38-3	S1-MBC	IgG1	3-9	4	AKDMVVVAIFGVGPFDY	1	1-6	4	LQDNYPLT	1	10.77	-	n.t.
HK CV38-179		S1-MBC	IgM	5-51	3	ARQRRPPGKRVLTMIVVYNDAFDI	1	1-33	3	QQYDNLFT	0	n.exp.		
HL CV38-179		S1-MBC	IgM	5-51	3	ARQRRPPGKRVLTMIVVYNDAFDI	1	1-40	2	QSYDSSLGSGV	2	n.exp.		
HL CV38-180		S1-MBC	IgG1	4-4	4	ARRAAAGPRPYDY	2	2-23	3	CSYAGFSTWV	6	n.exp.		
HK CV38-181		S1-MBC	IgA1	1-2	3	ARDLGSYLYGAFDI	1	3-11	4	QQRSNWPT	4	6.17	++	>250
HL CV38-182		S1-MBC	IgA1	1-69	2	AKELGYSYGAHRYFDL	3	1-40	2	QSYDSSLGSGV	0	11.73	++	250
HL CV38-183		S1-MBC	IgG1	3-53	6	ARGDGWDNYYGMDV	0	1-40	2	QSYDSSLGSGV	2	11.06	++	<25
HK CV38-184		S1-MBC	IgG1	4-39	5	ARGLGWFD	0	1-NL1	2	QQYYSTPRT	0	1.89	++	250
HL CV38-186		S1-MBC	IgG1	1-2	4	ARDQSPDILKSPFDY	1	2-23	3	CSYAGSSTFG	0	6.51	++	250
HL CV38-193		S1-MBC	IgA1	3-11	4	ARDISRNLHDFRPPYFDY	2	7-46	3	LLSYGARV	1	1.53	+	n.t.
HL CV38-194		S1-MBC	IgG1	4-59	3	ARHDVYSSGWYEGAFDI	2	1-40	3	QSYDSSLGSGV	3	0.09		
HL CV38-199		ASC	IgG3	4-59	4	ARYYQDFDY	0	1-44	1	AAWDDSLNGPYV	1	0.07		
HK CV38-201		ASC	IgG1	3-30	4	AKDIVLVAIIPVPIFDY	2	3-11	5	QQRSNWPT	1	0.07		
HL CV38-202		ASC	IgG1	3-33	3	ARDSSQQQLAYAFDI	2	3-1	2	QAWDSSIV	1	0.1		

mAb	Clonality	Source cell	Ig isotype	IGHV gene	IGHJ gene	CDR H3	SHM IGHV	IGKV/IGLV gene	IGKJ/IGLJ gene	CDR L3	SHM IGKV/IGLV	S1 reactivity (OD ratio)	RBD reactivity	Estimated IC <sub>50</sub> (ng/ml)
HL CV38-205		ASC	IgG1	4-30-2	6	ARDHYPIYYYGMDV	0	6-57	2	QSYDSSTVV	1	0.09		
HK CV38-206		ASC	IgA2	3-7	6	ARKGNAIDV	3	1-5	2	LQYNSYSWYT	1	0.08		
HL CV38-207	38-5	ASC	IgA1	4-30-4	3	AKIRVRAGFRWAFDI	22	2-14	3	SSYTNTNTLV	20	0.09		
HL CV38-208		ASC	IgM	4-39	2	AHQSGNSGPWYFDL	0	8-61	2	VLYMGSGIVV	1	0.08		
HL CV38-210		ASC	IgG1	4-39	4	ARHVEPDYGGNSFDY	0	1-40	1	QSYDSSLSGYV	1	0.11		
HL CV38-211		ASC	IgG1	3-9	6	AKDISNKWLRLTQPYSYYGLDV	3	2-8	1	SSYAGSNIPYV	7	0.08		
HL CV38-213		ASC	IgG1	3-23	3	AKVLIRNGYDILTGYPYDAFDI	0	2-14	2	SSYSSSTLV	0	3.15	+	n.t.
HL CV38-215		ASC	IgA1	3-30-3	4	ARDGYSAYDFGY	20	8-61	3	VLFMGSGTWV	18	n.exp.		
HK CV38-217		ASC	IgA1	4-30-2	4	ASGPAWELFDY	17	3-15	3	QSYHNWPL	15	0.10		
HK CV38-219		ASC	IgA1	4-39	4	ARQMRIGHTIVVPAALDY	2	3-20	1	QQYYSSPWT	5	0.07		
HK CV38-221		ASC	IgG1	3-66	4	ARGFGDYFFDY	4	3-20	2	QLLYT	1	10.74	++	25-250
HK CV38-222		ASC	IgG1	4-30-4	6	ARDPWQVTIFGVVIRYGMVDV	0	1-9	2	QLLNSPRT	3	0.09		
HL CV38-225		ASC	IgM	3-11	5	ARDLWFGRYWGNWLDLP	10	1-51	3	GTWDNSLSAAV	7	0.09		
HL CV38-227		ASC	IgA1	3-66	6	ASEGRTTGTVAYYYFAMDV	15	2-8	2	SSYAGRSNVV	15	0.09		
HK CV38-228	38-6	ASC	IgA1	4-31	4	AREKGTGDYYLDY	16	3-15	1	QQYNSWPRA	17	0.08		
HL CV38-229	38-5	ASC	IgA1	4-30-4	3	AKIRVRAGFRWAFDI	23	2-14	3	SSYTNTNTLV	20	0.09		
HL CV38-230		ASC	IgG1	3-53	4	ARDNSSNWYFDS	8	3-25	1	QSADSSGTYV	10	n.exp.		
HL CV38-231		ASC	IgG1	3-33	6	ARDGLDDDDYIWGSFKIRYYMDV	1	2-8	3	SSYSGTTNFAQ	19	0.08		
HL CV38-232		ASC	IgA1	3-23	4	ASGTYRLGDY	26	1-44	3	AAWDDSLDGPV	15	n.exp.		
HL CV38-233		ASC	IgG1	4-4	5	VTGGRWRFPD	16	2-11	3	CSYAGTYTYWL	12	0.08		
HK CV38-235	38-2	ASC	IgA1	3-23	4	VRDLSSSDPWYFDF	15	3D-20	1	QQYGDSPT	11	n.exp.		
HK CV38-236		ASC	IgG1	3-64	6	ARGGYEIVVVPDYYYGMDV	0	3-20	4	QQYKD	0	5.74	-	n.t.
HK CV38-238	38-7	ASC	IgM	3-30	6	AKDPLNCSSTRCYTAWIYYYYGMDV	0	2D-29	4	MQSIQLPLT	0	0.09		
HK CV38-240	38-7	ASC	IgG1	3-30	6	AKDSVKGYSSGWYYYYGMDV	0	2D-29	4	MQSIQLPLT	0	0.09		
HK CV38-242	38-2	ASC	IgA1	3-23	4	ARDLSSSDPWYFDF	14	3D-20	1	QQYGDSPT	11	0.08		
HK CV38-243		ASC	IgM	3-21	4	ARDRSGWYRNLFDY	1	2-28	5	MQUALQASIT	0	0.08		
HK CV38-245		ASC	IgG2	3-49	3	TRDFDHADSFDI	24	2-28	2	MQUALHTPRYT	9	0.09		
HK CV38-248		ASC	IgG2	3-30	4	AKGFYDSGP	12	2-30	2	MQGTHWKT	3	0.10		
HL CV38-251		ASC	IgA2	3-23	6	AKDQTVSFFYYGMDV	5	1-47	1	ATWDDSLSGYV	10	0.07		
HK CV38-252		ASC	IgM	1-3	4	ARDNTNTWFGSIEY	36	4-1	3	QQNYATPLT	21	n.exp.		
HL CV38-255		ASC	IgG2	3-9	4	VREATRGAHFDC	32	2-8	1	SSYVGFNNLDNFV	19	0.07		
HK CV38-257		ASC	IgM	4-34	2	ARRIYYGDLGNWNFDL	24	1-16	4	QQYNSYPLT	20	n.exp.		
HL CV38-259		ASC	IgG1	1-69	4	ATLYCSGGSCFPTGVFGY	0	7-46	3	LLSYSGARSWV	1	0.05		
HK CV38-263	38-6	ASC	IgA1	4-31	4	AREKGTGDYYLDS	21	3-15	1	QQYNSWPRA	21	0.09		
HK CV38-265		ASC	IgG1	3-23	6	AKDGHSMVRGVTMWGEFYYYYGMDV	0	3-15	2	QQYNNWPPYT	0	0.1		
HK CV38-270		ASC	IgG2	3-9	3	VRSRWQLTSSAFDM	33	1-9	4	QLLNKYPIT	25	n.exp.		
HK CV38-271	38-6	ASC	IgA1	4-31	5	AREKGTGDYYLDP	22	3-15	2	QQYNSWPRA	21	0.09		
HL CV38-273		ASC	IgG1	1-2	6	ARTYYYDSSGYRNYYYGMDV	4	2-18	1	SLYSSSTYV	0	0.18		
HK CV38-275		ASC	IgG1	3-15	4	TTDRGNSITIFGVVIIDRPY	0	3-20	2	QQYGSS	0	n.exp.		
HL CV38-276		ASC	IgA1	3-21	6	ARDEGSPGLDYYGMDV	1	2-14	2	SSYTSNTTLVV	4	0.08		
HL CV38-278	38-5	ASC	IgA1	4-30-4	3	AKIRVRAGFRWAFDI	21	2-14	3	SSYTNTNTLV	22	0.08		
HL CV38-281		ASC	IgG1	3-11	4	ARDMNYKYDSSGYPLLDY	0	1-44	3	AAWDDSLNGWV	0	0.15		
HK CV38-284		ASC	IgA1	3-49	4	IRARYYYDSSATFDY	18	1-39	4	QQCYSLPST	18	n.exp.		
HL CV38-286		ASC	IgA2	3-30	6	AKDASSPVYDFWGSYYNHLGMDV	0	3-21	3	QVWDDSSDQGV	2	0.11		
HK CV38-288		ASC	IgM	3-66	6	ARDYTVTGGVDGMDV	0	3-11	1	QQRSNWPPWT	0	n.exp.		
HK CV38-289		ASC	IgA1	3-23	4	VSRAAVGQPEY	44)	1D-12	3	QQAYTLPRVT	35	n.exp.		
HK CV48-103		S1-MBC	IgG1	3-49	6	SRFYDYWNTFGLLLGSLTFYHMDV	22	4-1	1	QQYCYTPWT	13	0.07		
HL CV48-104		S1-MBC	IgG1	1-69	5	ARDGQQLVRGWFPD	0	2-14	1	SSYSSSTLYV	2	6.93	++	>250
HL CV48-107		S1-MBC	IgG1	4-39	4	ASENDYGEHDY	0	4-60	2	ETWDSNTRKVV	1	0.1		
HL CV48-109		S1-MBC	IgG1	3-30	4	VKGDTSAYWPSLLIS	34	2-14	2	GSYATGSSPVV	17	0.10		

mAb	Clonality	Source cell	Ig isotype	IGHV gene	IGHJ gene	CDR H3	SHM IGHV	IGKV/IGLV gene	IGKJ/IGLJ gene	CDR L3	SHM IGKV/IGLV	S1 reactivity (OD ratio)	RBD reactivity	Estimated IC <sub>50</sub> (ng/ml)	
HK CV48-110	S1-MBC	IgA1	3-33	4	ARDARYSAYELPDYFFDL	17	1-5	1	QQYKGSWAT	10	n.exp.				
HL CV48-113	S1-MBC	IgG1	3-33	6	ARDGLDDDIWGSFKIRYYMDV	0	4-69	2	QTWGTGINVV	1	0.08				
HL CV48-119	S1-MBC	IgA2	3-23	4	AKTDRHWNHCD	18	2-14	2	SSYTGSSTLVA	18	0.08				
HL CV48-123	S1-MBC	IgM	1-3	4	ARNGGGLDQ	21	2-14	2	CSSTTSSTAV	12	n.exp.				
HK CV-X1-102	S1-MBC	IgG1	1-69	6	ARSPRPLIVVAEDGMDV	1	3-20	3	QQYGSPPFT	1	6.81	++	>250		
HL CV-X1-109	S1-MBC	IgG1	1-2	4	ARGPLFWDTAMANFDY	0	2-14	3	N/A	4	0.12				
HK CV-X1-111	S1-MBC	IgM	3-49	4	NRELHNSVVVGMVGY	17	4-1	2	HHYYSPPYA	7	0.16				
HK CV-X1-112	S1-MBC	IgM	3-23	4	AKVGSWGWAFFDY	16	3-15	1	QQYNKWPRT	5	0.09				
HL CV-X1-119	S1-MBC	IgG1	4-59	6	ARDRIMPLSYYYYYGMDV	0	1-44	3	AAWDDSLNGWV	0	0.17				
HK CV-X1-126	S1-MBC	IgG1	3-53	6	ARDLSEGGMDV	2	1-12	4	QQANGFPPL	2	11.78	++	25-250		
HK CV-X1-128	S1-MBC	IgG1	5-51	6	ARTYDFWSGGFYDMDV	3	3-11	3	QQRSNWPT	0	0.13				
HL CV-X1-131	S1-MBC	IgG1	3-30	4	ARMATTYPEHDPSLY	2	3-21	3	QVWDDSSDHVV	2	10.74	++	>250		
HK CV-X1-136	ASC	IgM	4-31	5	AAWRGFAATGFDS	21	1-9	3	QQLKSYPLT	7	0.1				
HK CV-X1-137	ASC	IgA1	1-8	3	ATEGTLTMTAGAFDL	26	1-12	2	QQTDFPYT	18	0.17				
HK CV-X1-140	ASC	IgA1	1-69	4	ARFGGTSQSSGYYGFDN	23	2-28	2	MQPLQTPYT	11	0.08				
HL CV-X1-141	ASC	IgG1	3-23	6	VTHDFPDWPPGGMDV	18	6-57	3	QSYDWSNQGCV	10	0.16				
HK CV-X1-142	ASC	IgG2	1-18	4	STRGMAPHDY	28	1-39	1	HQTYDTWT	33	n.exp.				
HK CV-X1-143	ASC	IgG1	3-11	4	ARDLGYSTRFDY	0	1-33	4	QQYDNLPLT	0	6.76	++	>250		
HK CV-X1-145	ASC	IgG1	5-51	4	AREDLTGPDY	8	2-30	2	MQGTHWPNT	1	0.16				
HL CV-X1-146	ASC	IgG1	3-23	4	ANNYYDNSGPDY	30	6-57	3	QSNDDGSPSWV	20	0.15				
HL CV-X1-150	ASC	IgG1	5-51	4	ARHLVCGGSCYPFDY	0	3-21	3	QVWDDSSDHQV	1	0.33				
HL CV-X1-153	ASC	IgG3	3-33	4	ARDWFWRLGGVDY	0	8-61	2	VLYMGSGLVV	2	0.16				
HL CV-X1-157	ASC	IgA1	3-48	6	ATSYDPSAAYSAHYAMDV	32	2-14	2	TSYTSLSPVV	20	0.09				
HK CV-X1-164	ASC	IgG1	1-2	6	ARSFGGFGGNYGMDV	3	1-39	5	QQSYSTPIT	0	0.13				
HL CV-X1-165	ASC	IgA2	3-48	4	ARDPIGTGSDY	13	1-51	2	GTWDDSLNAGV	9	0.13				
HK CV-X1-167	ASC	IgA2	3-74	5	ARAHSTTLYGWFDP	17	3-20	1	QHVVSSPLT	13	0.09				
HL CV-X1-171	ASC	IgA2	4-34	4	ARGFRKGSTFN	13	2-14	3	SSYTTSNTRT	15	0.09				
HK CV-X1-172	ASC	IgG1	3-48	6	ARDRLTIFGVAIDYYGMDV	0	1-12	4	QQANSFPALT	0	0.1				
HK CV-X1-173	ASC	IgG1	3-30	3	AKDYDSALCTGGTCTDFADF	27	1-27	1	QNYNSAPPWT	11	0.24				
HL CV-X1-174	ASC	IgG1	3-21	6	ATVQGDYVAGRAYYYGMDV	0	3-1	2	QAWDSSTAV	0	0.10				
HK CV-X1-175	ASC	IgG1	1-69	4	ARGLGTHLDC	1	4-1	3	QQYYSTGFT	1	1.99	-	n.t.		
HL CV-X1-177	ASC	IgG1	3-30	4	ARAETPASEIDY	0	3-1	2	QAWDSSHVV	1	0.08				
HK CV-X1-178	ASC	IgA1	3-49	6	TRDRPIDYGLHIYYGLDV	22	2-28	2	MQALQTPPT	8	0.1				
HK CV-X1-180	ASC	IgA1	4-39	5	LKDRTLQGNWFDP	26	3-11	5	QQRDWPVPT	14	0.09				
HL CV-X1-183	X1-1	ASC	IgG1	3-30	4	ASKSPERGSFDY	26	2-14	1	SSYTNSSSLYV	7	n.exp.			
HL CV-X1-188	ASC	IgM	4-4	5	AKGGGPIVA	14	4-60	2	ETWDSNTRL	8	0.08				
HL CV-X1-189	ASC	IgG1	3-23	6	AKGRYYDFWSPMPYGMV	1	2-14	3	SSYTSSTLGV	10	0.09				
HL CV-X1-190	X1-1	ASC	IgG1	3-30	4	ANTSPGRGSFDY	9	2-14	1	SSYTNSTLYV	13	0.08			
HK CV-X1-191	ASC	IgG1	4-31	4	ARQLRFLEWQYFDY	0	1-33	4	QQYDNLPT	0	n.exp.				
HK CV-X1-195	ASC	IgA1	3-64	4	VKGWGVKASSLGGDY	20	3-11	4	HQRSDWPRLT	11	n.exp.				
HK CV-X2-103	S1-MBC	IgA1	3-15	5	TTWRLGQDWDFP	17	1-39	4	QQSYSAPLT	14	0.81	++	>250		
HL CV-X2-105	S1-MBC	IgA1	3-73	6	TRRFDPNQRNDYYALDF	12	1-44	1	SAWDDSLNGYV	9	3.48	+	n.t.		
HK CV-X2-106	S1-MBC	IgG1	1-69	6	ATRKETTVTSLVYGMV	1	1-39	2	QQSYSTPYT	2	9.14	++	250		
HK CV-X2-107	X2-2	S1-MBC	IgA1	3-66	4	ARGKVGATGFY	15	3-20	2	QQYGSSPPMYT	8	n.exp.			
HK CV-X2-108	X2-2	S1-MBC	IgA1	3-66	4	ARGKVGATGFED	10	3-20	2	QQYGSSPPMYT	8	n.exp.			
HK CV-X2-109	S1-MBC	IgM	5-51	3	ARLAHYDRSGYSRADDADFV	7	3-15	2	QQYNNWPPVYT	2	6.81	++	>250		
HK CV-X2-117	X2-2	S1-MBC	IgA1	3-66	4	ARGKVGATGFED	10	3-20	2	QQYGSSPPMYT	9	0.08			
HK CV-X2-118	S1-MBC	IgG1	3-30	4	AKTGGPYCSGGSCYSALMDY	0	1-33	1	QQYDNLPT	0	n.exp.				
HK CV-X2-123	S1-MBC	IgA1	4-4	6	ARDRTREGYHDTLTGEFYFGTDV	33	3-20	2	QQYAMSPVT	27	n.exp.				

For clonality analysis mAbs from an identical donor were identified as clones when sharing the same V and J gene on both heavy and light chain and showing similarities within amino acid sequences of both CDR3. S1 reactivity was determined as a normalized optical density (OD) measured by SARS-CoV-2-S1 ELISA, with values above 0.5 considered as positive. From S1+ mAbs specificity to the RBD was determined using an RBD-ELISA and noted as negative (-), positive (+) or strongly positive (++), when detectable at 10 ng/ml. All strongly positive RBD+ mAbs were screened for neutralization of authentic SARS-CoV-2 (Fig. 1A), from which the IC<sub>50</sub> was estimated.

Abbreviations: ASC = antibody-secreting cell, S1-MBC = S1-SARS-CoV2-enriched memory B cell, Ig = immunoglobulin, HC = heavy chain, KC = kappa chain, LC = chain, IGHV/IGHJ = immunoglobulin heavy chain variable/joining gene, IGKV/IGKJ = immunoglobulin kappa chain variable/joining gene, IGLV/IGLJ = immunoglobulin lambda chain variable/joining gene, CDR = complementarity-determining region, SHM = somatic hypermutations, n.exp. = not expressed, n. t. = not tested.

**Supplementary Table ST3 | Public or common antibody response using VH3-53 and VH3-66 genes.**

mAb	IGHV	IGHJ	CDR H3	IGKV/IGLV	IGKJ/IGLJ	CDR L3
RBD-494 (Cao et al.)	3-53	6	ARDLVVYGMDV	1-9	4	QQLNSYPFT
HK CV07-202	3-53*01	6*02	ARDLYYYGMDV	1-9*01	4*01	QQLNNYSVT
HL CV07-275	3-66*01	4*02	ARDYYDSSGYSSGGLGY	2-8*01	1*01	SSYAGSNNFV
HL CV38-148	3-66*01	4*02	ARSAPLVGAYSGIYFDY	9-49*01	2*01	GADHGSGSNFVV
HK CV38-221	3-66*01	4*02	ARGFGDYFDY	3-20*01	2*01	QQLYT
HK CV38-113	3-53*04	4*02	ARGGRLADAAGDY	1-33*01	2*02	QQYDNLPSWT
HK CV38-139	3-53*01	4*02	ARGHYDLFDY	1-9*01	3*01	QQLNSYPPGT
HL CV38-183	3-53*01	6*02	ARGDGWDNYYYGMDV	1-40*01	2*01	QSYDSSLGSGV
HK CV-X1-126	3-53*04	6*02	ARDLSEGGMDV	1-12*01	4*01	QQANGFSAL

Abbreviations: IGHV/IGHJ = immunoglobulin heavy chain variable/joining gene, IGKV/IGKJ = immunoglobulin kappa chain variable/joining gene. IGLV/IGLJ = immunoglobulin lambda chain variable/joining gene, CDR = complementarity-determining region.



**Supplementary Table ST4 | Biophysical and functional characterization of the 18 most potent SARS-CoV-2 neutralizing mAbs.**

mAb	EC <sub>50</sub> (ng/ml)	K <sub>a</sub> (s <sup>-1</sup> )	K <sub>d</sub> (M <sup>-1</sup> s <sup>-1</sup> )	K <sub>D</sub> (M)	IC <sub>50</sub> (ng/ml)	ACE2 binding reduction (%)	Tissue reactivity
CV05-163	3.8	8.48 E+06	1.86 E-03	2.20 E-10	16.3	9.6	none
CV07-200	9.0	n/a	n/a	n/a	14.5	none	B / L*
CV07-209	4.1	2.40 E+07	1.44 E-04	6.00 E-12	3.1	73.9	none
CV07-222	5.5	2.98 E+07	2.07 E-04	6.97 E-12	7.8	36.9	B / L / C
CV07-250	8.7	4.05 E+06	2.28 E-04	5.64 E-11	3.5	59.9	none
CV07-255	4.8	n/a	n/a	n/a	14.5	51.6	L / H / C / K
CV07-262	12.1	4.27 E+06	3.37 E-04	7.90 E-11	7.1	25.5	none
CV07-270	14.2	n/a	n/a	n/a	82.3	7.5	L / H* / C
CV07-283	4.0	1.52 E+07	7.24 E-04	4.75 E-11	16.9	38.0	none
CV07-287	5.9	5.11 E+06	8.14 E-04	1.60 E-10	41.7	12.4	none
CV07-315	7.2	2.36 E+07	2.62 E-04	1.12 E-11	24.9	none	none
CV38-113	5.2	2.33 E+06	3.12 E-04	1.34 E-10	20.8	51.2	none
CV38-139	8.9	3.62 E+05	1.00 E-04	2.77 E-10	73.2	14.9	none
CV38-142	5.6	6.31 E+05	6.60 E-04	1.05 E-09	23.2	26.9	none
CV38-183	5.4	2.31 E+06	1.37 E-04	5.93 E-11	3.7	65.9	none
CV38-221	6.4	7.45 E+05	3.71 E-04	4.99 E-10	172.6	50.1	none
CV-X1-126	5.5	4.12 E+05	9.98 E-05	2.43 E-10	71.7	44.2	none
CV-X2-106	5.6	n/a	n/a	n/a	17.6	19.9	none

Abbreviations: EC<sub>50</sub> = half-maximal effective concentration, K<sub>a</sub> = association rate, K<sub>d</sub> = dissociation rate, K<sub>D</sub> = equilibrium dissociation constant, IC<sub>50</sub> = half-maximal inhibitory concentration, B = brain, L = lung, H = heart, C = colon, K = kidney. An asterisk (\*) indicates weak binding.

**Supplementary Table ST5 | X-ray data collection and refinement statistics.**

Data collection		
	CV07-250 + RBD	CV07-270 + RBD
Beamline	SSRL 12-1	SSRL 12-1
Wavelength (Å)	0.97946	0.97946
Space group	P 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	C 1 2 1
Unit cell parameters		
a, b, c (Å)	68.0, 80.1, 153.7	157.0, 151.8, 66.0
α, β, γ (°)	90, 90, 90	90, 95.4, 90
Resolution (Å) <sup>a</sup>	50.0–2.55 (2.59–2.55)	50.0–2.70 (2.75–2.70)
Unique reflections <sup>a</sup>	27,890 (2,659)	41,624 (2,089)
Redundancy <sup>a</sup>	8.8 (6.5)	4.7 (3.6)
Completeness (%) <sup>a</sup>	99.6 (98.9)	90.8 (90.8)
<I/σ> <sup>a</sup>	17.3 (1.1)	6.7 (1.1)
R <sub>sym</sub> <sup>b</sup> (%) <sup>a</sup>	11.9 (94.6)	19.9 (80.6)
R <sub>pim</sub> <sup>b</sup> (%) <sup>a</sup>	4.1 (38.9)	9.9 (50.5)
CC <sub>1/2</sub> <sup>c</sup> (%) <sup>a</sup>	99.5 (71.0)	97.6 (67.6)
Refinement statistics		
Resolution (Å)	43.2–2.55	49.7–2.72
Reflections (work)	27,883	39,568
Reflections (test)	2,656	2,055
R <sub>cryst</sub> <sup>d</sup> / R <sub>free</sub> <sup>e</sup> (%)	20.7/25.9	22.6/26.7
No. of atoms	4,525	9,233
Macromolecules	4,420	9,165
Glycans	28	28
Solvent	77	40
Average B-value (Å <sup>2</sup> )	52	44
Macromolecules	52	44
Fab	46	42
RBD	66	46
Glycans	100	77
Solvent	49	57
Wilson B-value (Å <sup>2</sup> )	51	39
RMSD from ideal geometry		
Bond length (Å)	0.005	0.007
Bond angle (°)	0.74	1.27
Ramachandran statistics (%)		
Favored	96.1	96.8
Outliers	0.2	0.0
PDB code	6XKQ	6XKP

<sup>a</sup> Numbers in parentheses refer to the highest resolution shell.

<sup>b</sup>  $R_{sym} = \sum_{hkl} \sum_i |I_{hkl,i} - \langle I_{hkl} \rangle| / \sum_{hkl} \sum_i I_{hkl,i}$  and  $R_{pim} = \sum_{hkl} (1/(n-1))^{1/2} \sum_i |I_{hkl,i} - \langle I_{hkl} \rangle| / \sum_{hkl} \sum_i I_{hkl,i}$  where  $I_{hkl,i}$  is the scaled intensity of the  $i^{\text{th}}$  measurement of reflection  $h, k, l$ ,  $\langle I_{hkl} \rangle$  is the average intensity for that reflection, and  $n$  is the redundancy.

<sup>c</sup>  $CC_{1/2}$  = Pearson correlation coefficient between two random half datasets.

<sup>d</sup>  $R_{cryst} = \sum_{hkl} |F_o - F_c| / \sum_{hkl} |F_o| \times 100$ , where  $F_o$  and  $F_c$  are the observed and calculated structure factors, respectively.

<sup>e</sup>  $R_{free}$  was calculated as for  $R_{cryst}$ , but on a test set comprising 5% of the data excluded from refinement.

**Supplementary Table ST6 | Hydrogen bonds and salt bridges identified at the antibody-RBD interface using the PISA program.**

CV07-250	Distance (Å)	SARS-CoV-2 RBD
<b>Hydrogen bonds</b>		
H:TYR98[N]	3.0	A:ALA475[O]
H:ASN31[ND2]	3.4	A:SER477[OG]
H:ASN100C[ND2]	3.8	A:GLY485[O]
H:ASN100C[ND2]	2.9	A:PHE486[O]
H:ASN97[ND2]	2.8	A:ASN487[OD1]
H:ASN97[ND2]	2.7	A:TYR489[OH]
H:TYR100B[N]	3.5	A:TYR489[OH]
H:ASP96[OD1]	3.0	A:SER477[N]
H:ASP96[OD2]	2.7	A:SER477[OG]
H:ASP96[OD2]	3.5	A:THR478[N]
H:ASP96[OD2]	2.9	A:THR478[OG1]
H:SER95[OG]	2.9	A:ASN487[ND2]
H:PHE100[O]	3.4	A:TYR489[OH]
L:SER27A[OG]	3.2	A:TYR505[OH]
L:HIS31[N]	3.1	A:GLN493[OE1]
L:SER67[OG]	3.5	A:GLY446[O]
L:GLY68[N]	3.1	A:GLY446[O]
L:GLY68[N]	3.1	A:TYR449[OH]
L:ASN69[N]	3.8	A:GLN498[OE1]
L:ASN69[ND2]	3.7	A:GLN498[OE1]
L:TYR49[OH]	3.5	A:PHE486[N]
<b>CV07-270</b>		
CV07-270	Distance (Å)	SARS-CoV-2 RBD
<b>Hydrogen bonds</b>		
H:TYR100B[OH]	2.8	A:SER349[OG]
H:SER98[N]	3.2	A:GLY447[O]
H:SER98[OG]	3.8	A:GLY447[O]
H:SER98[OG]	3.2	A:ASN448[OD1]
H:ARG100G[NH2]	2.9	A:GLU484[OE1]
H:ARG100G[NH1]	3.2	A:GLU484[OE2]
H:ARG100G[NH2]	3.0	A:GLU484[OE2]
H:THR28[OG1]	3.2	A:LYS444[NZ]
H:ASP31[OD1]	2.7	A:ARG346[NH1]
H:ASP31[OD2]	2.7	A:LYS444[NZ]
H:SER98[O]	2.7	A:TYR449[N]
H:SER98[O]	3.3	A:ASN450[N]
H:TYR100B[OH]	3.6	A:SER349[N]
<b>Salt bridges</b>		
H:ARG100G[NH2]	2.9	A:GLU484[OE1]
H:ARG100G[NH1]	3.2	A:GLU484[OE2]
H:ARG100G[NH2]	3.0	A:GLU484[OE2]
H:ASP31[OD1]	2.7	A:ARG346[NH1]
H:ASP31[OD1]	3.4	A:ARG346[NE]
H:ASP31[OD2]	2.7	A:LYS444[NZ]

**Supplementary Table ST7 | Histopathological scoring of lung tissue from COVID-19 hamster model.**

Animal number	Time point (dpi)	pneumonia					Epithelial cell necrosis of bronchi <sup>a</sup>	Bronchial inflammation <sup>a</sup>	Hyperplasia of bronchial epithelia cells <sup>b</sup>	Alveolar epithelial cell necrosis	Hyperplasia type II alveolar epithelial cells <sup>b</sup>	Alveolar edema <sup>c</sup>	Perivascular edema <sup>c</sup>	Perivascular lymphocytic cuffing	Endotheliitis	<sup>a</sup> Bronchitis score	<sup>b</sup> Regeneration score	<sup>c</sup> Edema score
		% Affected lung tissue	Degree of inflammation*	Lymphocytes	Macrophages	Neutrophils												
P1	3	<5	1.0	0.0	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0
P2	3	<5	1.0	1.0	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0
P3	3	5	1.0	1.0	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
T1	3	10	1.5	1.0	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0
T2	3	25	3.0	2.5	2.0	3.5	3.5	4.0	0.0	3.0	2.0	1.5	0.0	2.0	2.0	3.8	1.0	0.8
T3	3	15	2.0	2.0	2.0	2.0	0.0	0.0	0.0	2.0	1.0	0.0	1.0	1.0	0.0	0.0	0.5	0.5
C1	3	15	2.5	2.0	2.0	3.0	2.5	3.0	0.0	3.0	1.0	2.0	1.0	1.0	2.0	3.0	0.5	1.5
C2	3	20	2.5	2.5	2.0	2.5	2.5	3.0	0.0	2.0	1.0	0.0	3.0	1.5	2.0	3.0	0.5	1.5
C3	3	20	2.5	2.0	2.5	2.5	2.0	2.0	0.0	3.0	2.0	0.0	2.0	1.0	2.0	2.0	1.0	1.0
P4	5	5-10	2.0	2.0	2.0	1.5	0.0	0.0	0.0	2.0	2.0	0.0	1.5	1.0	0.0	0.0	1.0	0.8
P5	5	<5	1.0	1.0	1.0	1.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.5
P6	5	15	2.0	2.0	2.0	2.0	0.0	0.0	0.0	2.0	2.0	0.0	0.0	2.0	0.0	0.0	1.0	0.0
T4	5	5-10	2.0	2.0	1.5	1.0	0.0	0.0	0.0	1.0	2.0	0.0	0.0	2.0	0.0	0.0	1.0	0.0
T5	5	25	3.0	3.0	2.0	3.0	2.0	2.0	0.0	3.0	3.0	2.0	2.0	3.0	3.0	2.0	1.5	2.0
T6	5	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C4	5	80	4.0	4.0	3.0	3.0	3.0	3.0	3.0	3.0	4.0	3.0	3.5	3.0	3.5	3.0	3.5	3.3
C5	5	15-20	2.5	3.0	2.5	2.0	2.0	2.0	1.5	2.0	2.0	2.5	0.0	3.0	2.0	2.0	1.8	1.3
C6	5	50	4.0	3.5	3.0	3.0	3.0	3.0	4.0	2.5	4.0	3.5	4.0	3.5	3.0	3.0	4.0	3.8
P7	13	20	2.0	2.0	2.0	1.0	0.0	0.0	0.0	1.5	0.0	1.5	0.0	1.5	0.0	0.0	0.8	0.8
P8	13	30	2.0	2.0	2.0	2.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	2.0	0.0	0.0	1.0	0.0
P9	13	30	2.0	2.0	2.0	2.0	0.0	1.0	1.0	1.5	0.0	0.0	0.0	2.0	0.0	0.5	1.5	0.0
T7	13	15	2.0	2.0	2.0	1.5	0.0	0.0	0.0	1.5	0.0	0.0	0.0	2.0	0.0	0.0	1.0	0.0
T8	13	5	1.0	1.5	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.5	0.0
T9	13	20	1.5	1.5	1.0	1.5	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.5	0.0	0.0	0.8	0.0
C7	13	5	1.0	1.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.8	0.0
C8	13	40	2.0	2.0	2.0	2.0	0.0	1.0	1.0	1.5	0.0	0.0	1.5	2.0	0.0	0.5	1.5	0.0
C9	13	10	1.0	1.0	1.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.5	0.8	0.0

Histopathological scoring of formalin-fixed paraffin-embedded lung tissue from hamsters of experimental groups as abbreviated (P = prophylactic, T = therapeutic, C = control) at indicated days post infection (dpi). Degree of inflammation <sup>(\*)</sup> is scaled as (1) minimal, (2) mild,

(3) moderate or (4) severe. For all other parameters rating refers to occurrence rate from (1) sporadic, (2) mild, (3) moderate to (4) severe.

Scores were assessed as means from parameters with corresponding letters as indicated.